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Abstract:   ? ?
Mutations in MECP2 cause Rett syndrome (RTT), an X-linked neurological disorder  ? ?
characterized by regressive loss of neurodevelopmental milestones and acquired psychomotor  ? ?
deficits. However, the cellular heterogeneity of the brain impedes an understanding of how  ? ?
MECP2 mutations contribute to RTT. Here we developed a Cre-inducible method for cell type- ? ?
specific biotin tagging of MeCP2 in mice. Combining this approach with an allelic series of  ? ?
knockin mice carrying frequent RTT mutations (T158M and R106W) enabled the selective  ? ?
profiling of RTT-associated nuclear transcriptomes in excitatory and inhibitory cortical neurons.  ? ?
We found that most gene expression changes are largely specific to each RTT mutation and cell  ? ?
type. Lowly expressed cell type-enriched genes are preferentially disrupted by MeCP2  ? ?
mutations, with upregulated and downregulated genes reflecting distinct functional categories.  ? ?
Subcellular RNA analysis in MeCP2 mutant neurons further reveals reductions in the nascent  ? ?
transcription of long genes and uncovers widespread post-transcriptional compensation at the  ? ?
cellular level. Finally, we overcame X-linked cellular mosaicism in female RTT models and  ? ?
identified distinct gene expression changes between neighboring wild-type and mutant neurons,  ? ?
altogether providing contextual insights into RTT etiology that support personalized therapeutic  ? ?
interventions.  ? ?
  ? ?
  ? ?
  ? ?
  ? ?
  ? ?
  ? ?
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Introduction  ? ?
RTT is a progressive X-linked neurological disorder that represents one of the most common  ? ?
causes of intellectual disability among young girls. Patients experience a characteristic loss of  ? ?
acquired social and psychomotor skills and develop stereotyped hand movements, breathing  ? ?
irregularities, and seizures after 6-18 months of normal development
1
. Approximately 95% of  ? ?
RTT cases are mapped to the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2), a  ? ?
ubiquitously expressed protein that is highly enriched in postmitotic neurons
2,3
. The majority of  ? ?
RTT-associated mutations cluster within two functionally distinct domains of MeCP2. The  ? ?
Methyl-CpG Binding Domain (MBD) allows MeCP2 to bind to methylated cytosines
4
. The  ? ?
Transcriptional Repression Domain (TRD) mediates protein-protein interactions with histone  ? ?
deacetylase-containing co-repressors, such as the NCoR-SMRT and mSin3A complexes
57
.  ? ?
These domains support MeCP2 as a chromatin factor that mediates transcriptional repression
7,8
,  ? ?
although transcriptional activation by MeCP2 is also reported
911
.  ? ?
Different mutations in MECP2, together with random X-chromosome inactivation (XCI),  ? ?
underlie a spectrum of clinical severity in RTT patients
12
. Among the most frequent RTT  ? ?
mutations, three are missense mutations in the MeCP2 MBD, including R106W (2.76% of RTT  ? ?
patients), R133C (4.24%), and T158M (8.79%)
13
. Typical RTT patients bearing the R133C  ? ?
mutation display milder clinical symptoms, whereas patients carrying the T158M or R106W  ? ?
mutation exhibit moderate or severe symptoms, respectively
12
. Although the clinical severity of  ? ?
these mutations scales with their effects on MeCP2 binding affinity to methylated DNA
1417
, this  ? ?
relationship is not fully understood on a molecular level. Mouse models carrying RTT mutations  ? ?
can recapitulate this phenotypic variability, but most studies are limited to hemizygous male  ? ?
mice
1721
. Despite that RTT predominantly affects heterozygous females, an experimental  ? ?
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strategy to selectively identify gene expression changes from Mecp2 mutant-expressing cells in a  ? ?
mosaic female brain has not yet been developed.  ? ?
Given that MeCP2 is a chromatin-bound nuclear protein, the identification of MeCP2  ? ?
transcriptional targets in the brain remains key towards illuminating RTT etiology
22
. However,  ? ?
target identification is confounded by the cellular heterogeneity of the brain, which contains  ? ?
multiple intermixed cell types that differ in morphology, function, electrophysiological  ? ?
properties, and transcriptional programs
2325
. Analyses using heterogeneous brain tissues obscure  ? ?
cell type-specific gene expression changes, impeding the assessment of MeCP2 function at the  ? ?
transcriptional level
26
. The identification of transcriptional targets is further complicated by the  ? ?
widespread binding patterns of MeCP2 to methylated cytosines (mCpG and mCpA)
8,27,28
 or  ? ?
unmethylated GC-rich regions
29
 throughout the genome.   ? ?
In this study, we addressed the confounding effects of cellular heterogeneity by  ? ?
engineering genetically modified mice whereby MeCP2 is labeled with biotin using Cre-Lox  ? ?
recombination. To understand the molecular impact of RTT mutations on cell type-specific gene  ? ?
expression in vivo, we also developed an allelic series of knockin mice bearing one of two  ? ?
frequent RTT missense mutations, T158M and R106W. When combined with Fluorescence- ? ?
Activated Cell Sorting (FACS), this strategy allows for the isolation of neuronal nuclei from  ? ?
targeted cell types, effectively circumventing cellular heterogeneity in the mouse brain and X- ? ?
linked mosaicism in female mice. Our findings support a contextualized model by which cell  ? ?
autonomous and non-autonomous transcriptional changes in different cell types contribute to the  ? ?
molecular severity of neuronal deficits in RTT, providing new directions for therapeutic  ? ?
development.  ? ?
  ? ?
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  ? ?
Results  ? ?
Engineering a System to Genetically Biotinylate MeCP2 In Vivo: Biotin-mediated affinity  ? ?
tagging has been widely utilized in cell and animal models for multiple experimental approaches  ? ?
because of the strong (Kd = 4x10
-14
M) and specific interaction between biotin and avidin  ? ?
protein
30
. We exploited this approach to investigate MeCP2 function by using homologous  ? ?
recombination to insert a short 23-amino acid affinity tag immediately upstream of the Mecp2  ? ?
stop codon (Fig. 1a and Supplementary Fig. 1a). This tag comprises a TEV protease cleavage site  ? ?
and a 15-amino acid biotinylation consensus motif (termed Tavi, TEV and Avidin-binding) that  ? ?
can be post-translationally labeled with biotin by the E. coli biotin ligase, BirA. To biotinylate  ? ?
the tag in cell types of interest, we also generated Cre-dependent BirA transgenic mice (herein  ? ?
R26
cBirA
; Supplementary Fig. 1b). Therefore, upon crossing these mice to a cell type-specific Cre  ? ?
line, BirA is expressed and subsequently biotinylates MeCP2-Tavi (Fig. 1b). We used EIIa-Cre
31
  ? ?
to ubiquitously express BirA (R26
BirA
) and confirmed that MeCP2 is specifically biotinylated in  ? ?
vivo only when BirA is expressed and the Tavi tag is present (Fig. 1c and Supplementary Fig.  ? ?
1c).  ? ?
 To examine the possibility that tagging MeCP2 adversely affects its function, we  ? ?
assessed MeCP2 expression levels, DNA binding, and protein-protein interactions in 20-week  ? ? ?
old Mecp2
Tavi/y
 (herein TAVI) and littermate Mecp2
+/y
 (WT) mice. We found that total MeCP2  ? ? ?
protein, but not RNA, is significantly reduced by ~40% in TAVI mice, and a similar trend  ? ? ?
towards ~40% reduction is also observed among soluble and chromatin-bound protein fractions  ? ? ?
(Supplementary Fig. 1d-f). However, Tavi-tagged and untagged MeCP2 both exhibit comparable  ? ? ?
levels of chromatin binding at high and low affinity genomic sites, including highly methylated  ? ? ?
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major satellite repeats and IAP elements, and MeCP2-Tavi remains associated with the NCoR- ? ? ?
SMRT co-repressor (Supplementary Fig. 1g-h). Although a 50% reduction in MeCP2 expression  ? ? ?
is sufficient to cause hypoactivity and subtle behavioral phenotypes in mice
32
, TAVI mice appear  ? ? ?
similar to WT mice and do not display overt RTT-like features using phenotypic scoring
33
 over  ? ? ?
an observational period of 20 weeks (Fig. 1g-j, Supplementary Fig. 1i, and data not  ? ? ?
shown/B.S.J).   ? ? ?
  ? ? ?
MeCP2 Missense Mutations Recapitulate RTT-like Phenotypes in Mice: To examine the  ? ? ?
molecular relationship between MeCP2 affinity for methylated DNA and phenotypic severity,  ? ? ?
we generated independent Mecp2
T158M-Tavi
 (herein T158M) and Mecp2
R106W-Tavi
 (R106W) knock- ? ? ?
in mice in parallel with TAVI mice (Fig. 1a). Relative to TAVI controls, we found that T158M  ? ? ?
and R106W mice both display a ~70-80% reduction in MeCP2 protein expression despite  ? ? ?
equivalent levels of mRNA at 6 weeks of age (Fig. 1e, Supplementary Fig. 1j), similar to other  ? ? ?
mouse models bearing MeCP2 MBD mutations
17,18,21
. However, there is a trend towards  ? ? ?
relatively higher MeCP2 protein levels in T158M than R106W mice across development  ? ? ?
(Supplementary Fig. 2a). Immunofluorescent (IF) staining of hippocampal sections from T158M  ? ? ?
and R106W mice revealed diffusely distributed MeCP2 throughout the nucleus that accompanied  ? ? ?
a loss of localization to heterochromatic foci, supporting the impaired binding of mutant MeCP2  ? ? ?
to mCpGs in vivo (Fig. 1d). Streptavidin IF, which is noticeably lower in Mecp2 mutant mice,  ? ? ?
also confirmed a loss of mutant MeCP2 localization to heterochromatic foci and further  ? ? ?
illustrated a redistribution of mutant MeCP2 to the nucleolus (Fig. 1d and Supplementary Fig.  ? ? ?
2b-c), a property reminiscent of GFP-tagged MeCP2 lacking its MBD
34
.   ? ? ?
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 Using sub-nuclear fractionation, we confirmed that a greater proportion of MeCP2  ? ? ?
T158M or R106W protein occupies the soluble fraction when compared to WT or TAVI protein  ? ? ?
(Supplementary Fig. 2d), consistent with the loss of chromatin binding in mutant mice (Fig. 1d).  ? ? ?
By further extracting chromatin-bound MeCP2 with different salt concentrations, we found that  ? ? ?
MeCP2 R106W is more readily released at lower salt concentrations (200mM NaCl) than  ? ? ?
MeCP2 WT, TAVI, or T158M protein, suggesting that MeCP2 R106W has the lowest binding  ? ? ?
affinity for chromatin (Fig. 1f and Supplementary Fig. 2e). Phenotypic comparisons revealed that  ? ? ?
T158M and R106W mice both exhibit RTT-like features similar to that of Mecp2-null mice,  ? ? ?
including decreased brain and body weight, and an age-dependent increase in phenotypic score  ? ? ?
(Fig. 1g-i). Although lifespan is significantly reduced in all three Mecp2 mutant mice, the  ? ? ?
median survival of R106W mice more closely resembles that of Mecp2-null than T158M mice  ? ? ?
(Fig. 1j). Both mutations demonstrated a significant difference in survival curves (T158M  ? ? ?
median survival = 14 weeks; R106W median survival = 10 weeks; Mantel Cox P = 0.012).  ? ? ?
Together, these data suggest that T158M and R106W mutations represent a partial and complete  ? ? ?
loss-of-function, respectively.  ? ? ?
  ? ? ?
Genetic Biotinylation Permits Cell Type-specific Transcriptional Profiling: We next devised  ? ? ?
a biotinylation-based strategy for cell type-specific nuclei isolation and transcriptional profiling  ? ? ?
(Fig. 2a-b). We used the NeuroD6/NEX-Cre line
35
 to drive BirA expression and MeCP2-Tavi  ? ? ?
biotinylation in forebrain excitatory neurons (Fig. 2a and Supplementary Fig. 3a-g).  ? ? ?
Quantification of pan-neuronal (NeuN), pan-inhibitory (GAD67), and inhibitory-specific  ? ? ?
(parvalbumin, somatostatin and calretinin) neuronal markers in the somatosensory cortex of  ? ? ?
Mecp2
Tavi/y
;R26
cBirA/+
;NEX
Cre/+
 (herein NEX-Cre) mice demonstrated that biotinylation occurs in  ? ? ?
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~80% of NeuN+ cortical neurons devoid of inhibitory markers (Supplementary Fig. 3h). FACS  ? ? ?
using stained cortical nuclei from NEX-Cre mice identified three distinct nuclear populations  ? ? ?
(Fig. 2c). RT-PCR for cell type-specific markers confirmed that NeuN+Biotin+ nuclei reflect  ? ? ?
excitatory neurons, whereas NeuN+Biotin- nuclei represent a mixture of inhibitory interneuron  ? ? ?
subtypes (Fig. 2c-d). Astrocytic, microglial and oligodendrocytic markers are restricted to the  ? ? ?
third, non-neuronal population of NeuN-Biotin- nuclei (Fig. 2c-d). We also used the Dlx5/6-Cre  ? ? ?
line
36
 to drive BirA expression in forebrain GABAergic neurons and obtained results inverse to  ? ? ?
that of NEX-Cre (Fig. 2a and Supplementary Fig. 3a-j), confirming that MeCP2-Tavi is reliably  ? ? ?
biotinylated in Cre-defined cell types.  ? ? ?
Because MeCP2 is known to modulate transcription
22
, nuclear RNA-seq would afford an  ? ? ?
unique opportunity to study the primary effects of RTT mutations on gene expression. We thus  ? ? ?
performed transcriptional profiling in 6-week old male mice near the onset of RTT-like  ? ? ?
phenotypes. We employed the NEX-Cre driver and isolated cortical excitatory and inhibitory  ? ? ?
nuclei from T158M, R106W and TAVI mice via FACS, followed by total RNA-seq  ? ? ?
(Supplementary Table 1). Biological replicates were well-correlated (Fig. 2e), and ~74% of total  ? ? ?
reads mapped to introns, serving as a proxy for chromatin-associated transcriptional activity
37,38
.   ? ? ?
Unsupervised hierarchical clustering shows that replicate transcriptomes from cortical excitatory  ? ? ?
and inhibitory neurons in TAVI mice are highly correlated by cell type, and genic-mapped reads  ? ? ?
illustrate selectively expressed genes in each cell type (Fig. 2e-f and Supplementary Fig. 4a). We  ? ? ?
identified 9,379 differentially expressed genes (DEGs, FDR < 0.05) between excitatory and  ? ? ?
inhibitory neurons, the majority (86.9%) of which comprise protein-coding genes (Table 1 and  ? ? ?
Supplementary Fig. 4b). Among the protein-coding fraction of cell type-enriched DEGs, 3,958  ? ? ?
genes (0.15  4.70 fold change) display Gene Ontology (GO) functions consistent with  ? ? ?
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glutamatergic pyramidal cell types (EXC-enriched; Supplementary Fig. 4c), whereas the  ? ? ?
remaining 4,194 genes (0.17  7.77 fold change) exhibit GO functions consistent with  ? ? ?
metabolically active GABAergic interneurons (INH-enriched; Supplementary Fig. 4d).  ? ? ?
   ? ? ?
Protein-Coding Genes are More Severely Affected in R106W Mice: We next compared  ? ? ?
nuclear gene expression profiles in excitatory and inhibitory neurons between mutant (T158M,  ? ? ?
R106W) and control (TAVI) mice to identify and characterize DEGs associated with the  ? ? ?
appearance of RTT-like phenotypes (Fig. 3a). We identified more DEGs in excitatory and  ? ? ?
inhibitory neurons of R106W than T158M mice, indicating that the number of misregulated  ? ? ?
genes positively scales with the severity of the Mecp2 mutation (Fig. 3b and Table 1). More than  ? ? ?
90% of MeCP2 DEGs are protein-coding genes (Supplementary Fig. 5a), significantly higher  ? ? ?
than the percentage of protein-coding genes in the genome (60.4%), or among actively expressed  ? ? ?
(77.7-78.3%) and cell type-enriched (86.2-87.7%) genes (Supplementary Fig. 4b). We therefore  ? ? ?
excluded non-coding genes from further analyses. We note that the number and percentage of  ? ? ?
protein-coding DEGs overlapping between T158M and R106W genotypes is greater in inhibitory  ? ? ?
(107 genes) than excitatory neurons (69 genes). Moreover, overlapping DEGs tend to be  ? ? ?
misregulated in the same direction (Fig. 3c).   ? ? ?
The median fold change of T158M and R106W DEGs is small in mutant neurons  ? ? ?
compared to overall differences in gene expression between excitatory and inhibitory neurons  ? ? ?
(Supplementary Fig. 5b and Table 1). We further compared fold changes between T158M and  ? ? ?
R106W DEGs, limiting our analysis to protein-coding genes that overlap between genotypes to  ? ? ?
account for disproportionate numbers of DEGs. Within this subset, we found that the median  ? ? ?
fold change among upregulated and downregulated DEGs is consistently higher in both cell  ? ? ?
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types of R106W mice than those of T158M mice (Fig. 3c), consistent with a more severe  ? ? ?
phenotype in R106W mice.    ? ? ?
  ? ? ?
Transcriptional Features of T158M and R106W DEGs: We next compared MeCP2 DEGs  ? ? ?
across excitatory and inhibitory neurons and found limited overlap between the two cell types  ? ? ?
(6.2% of T158M DEGs, 10.7% of R106W DEGs; Fig. 3d), indicating that most DEGs reflect cell  ? ? ?
type-specific transcriptional changes. Indeed, EXC/INH-enriched genes are significantly  ? ? ?
overrepresented among MeCP2 DEGs in each cell type, comprising ~70-80% of genes (Fig. 3e  ? ? ?
and Table 1). Moreover, EXC- and INH-enriched genes are preferentially downregulated and  ? ? ?
upregulated, respectively, in each cell type (Fig. 3e and Supplementary Fig. 5c).  ? ? ?
 We next performed a pre-ranked Gene Set Enrichment Analysis (GSEA, FDR < 0.1) to  ? ? ?
determine whether upregulated and downregulated DEGs represent functionally distinct  ? ? ?
categories. Upregulated DEGs in T158M and R106W mice are both primarily associated with  ? ? ?
transcriptional regulation. These include DNA-binding transcriptional activators, repressors, and  ? ? ?
chromatin remodelers, most of which tend to be INH-enriched genes (Fig. 3f and Supplementary  ? ? ?
Fig. 5d). Significant functional categories associated with downregulated DEGs, however, are  ? ? ?
specifically detected in R106W excitatory neurons and enriched for post-synaptic membrane  ? ? ?
proteins, including various ion channels, synaptic scaffolding proteins, and ionotropic glutamate  ? ? ?
receptors (Fig. 3f). Although significant gene functions were not identified among  ? ? ?
downregulated DEGs in inhibitory neurons using our GSEA FDR cutoff, gene functions  ? ? ?
associated with upregulated DEGs in R106W inhibitory neurons are related to cellular  ? ? ?
metabolism and signal transducer activity (Supplementary Fig. 5e).   ? ? ?
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Upon examining the relative expression levels of MeCP2 DEGs using Fragments Per  ? ? ?
Kilobase of transcript per Million mapped reads (FPKM), we noticed that T158M, R106W, and  ? ? ?
overlapping DEGs display significantly lower FPKM values relative to total expressed genes in  ? ? ?
each cell type (Fig. 3g). To exclude the possibility of gene filtering biases associated with RNA- ? ? ?
seq, we randomly selected 12 low-expressing DEGs that overlap between both mutations and  ? ? ?
independently measured their primary and mature RNA transcripts in excitatory neuronal nuclei  ? ? ?
using RT-PCR (Supplementary Table 2). We found that 10 out of 12 genes show significant gene  ? ? ?
expression changes that resemble those using RNA-seq (83.3% positive validation rate;  ? ? ?
Supplementary Fig. 6a-b), confirming that genes with low transcriptional activity are indeed  ? ? ?
affected by MeCP2 mutations. To examine whether lowly expressed genes are selectively  ? ? ?
enriched for MeCP2 DEGs, we binned actively expressed genes from each cell type into four  ? ? ?
percentiles (Q1-Q4) according to expression level. EXC- and INH-enriched genes served as  ? ? ?
reference distributions across percentiles for each cell type (Supplementary Fig. 6c). In  ? ? ?
comparison, T158M and R106W DEGs are preferentially enriched in Q1, the bottom 25
th
  ? ? ?
percentile of actively expressed genes, in both excitatory and inhibitory neurons (Fisher Exact  ? ? ?
one-tailed P, T158M: EXC = 1.11e-07, INH = 2.03e-04; R106W: EXC = 4.04e-08, INH = 1.50e- ? ? ?
02; Supplementary Fig. 6c). Between the two mutations, T158M DEGs are more likely to be  ? ? ?
lowly expressed than R106W DEGs (Fisher Exact Odds Ratio (OR) for Q1, T158M: EXC = 3.1,  ? ? ?
INH = 3.2; R106W: EXC = 2.0, INH = 1.3; Supplementary Fig. 6c). Accordingly, R106W- ? ? ?
specific DEGs have significantly higher FPKM values than T158M DEGs in both cell types and  ? ? ?
are predominantly downregulated in R106W neurons (Fig. 3g and Supplementary Fig. 6d). This  ? ? ?
preferential downregulation of high-expressing genes appears consistent with the specific loss of  ? ? ?
synaptic gene functions in R106W excitatory neurons (Fig. 3f-g and Supplementary Fig. 6d).  ? ? ?
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  ? ? ?
Subcellular RNA Pools Reveal Global Transcriptional and Post-transcriptional Changes:  ? ? ?
Two recent reports implicate MeCP2 in the transcriptional repression of long genes, which are  ? ? ?
preferentially upregulated in the neurons of multiple RTT models
27,39
. We therefore examined  ? ? ?
the possibility that genome-wide transcriptional changes may correlate with T158M and R106W  ? ? ?
phenotypic and molecular severity. Similar to those studies, we sorted and binned expressed  ? ? ?
protein-coding genes according to gene length and measured the mean fold change in Mecp2  ? ? ?
mutant neurons. Notably, nuclear transcriptomes revealed a striking inversion of previously  ? ? ?
reported gene expression changes whereby short ( 100kb in gene length) and long (> 100kb in  ? ? ?
gene length) genes trend towards upregulation and downregulation, respectively, in a length- ? ? ?
dependent manner (Supplementary Fig. 7a).  ? ? ?
 Although most nuclear RNAs comprise intron-containing pre-mRNA transcripts on  ? ? ?
chromatin, the presence of processed mRNA transcripts awaiting nuclear export may potentially  ? ? ?
confound the assessment of transcriptional events
40
. We therefore performed global nuclear run- ? ? ?
on with high-throughput sequencing (GRO-seq
41
) to directly assess de novo transcriptional  ? ? ?
activity by RNA polymerase in cortical nuclei of TAVI and R106W mice. Similar to sorted  ? ? ?
nuclear RNA, the nascent transcription of short and long genes in R106W neurons is  ? ? ?
predominantly increased and decreased, respectively (Fig. 4a). LOESS local regression of DEGs  ? ? ?
that were identified in R106W excitatory and inhibitory neurons also revealed a similar overall  ? ? ?
trend towards the preferential downregulation of long genes (Fig. 4a). The genome-wide trend  ? ? ?
we observe in sorted nuclear RNA thus represents a primary effect at the transcriptional level,  ? ? ?
prompting us to further investigate if the length-dependent upregulation of long genes that was  ? ? ?
previously reported may represent an indirect effect of MeCP2-dependent transcriptional  ? ? ?
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deregulation. To test this, we resected cortical tissue from TAVI and R106W mice, and subjected  ? ? ?
each cortical half to whole cell or nuclear RNA isolation in parallel, followed by sequencing.  ? ? ?
Cortical whole cell RNA from mutant mice displayed a length-dependent increase in the mean  ? ? ?
expression of long genes (Fig. 4b), similar to what was previously described
27,39
. In contrast,  ? ? ?
cortical nuclear RNA isolated from the same TAVI and R106W mice exhibited a length- ? ? ?
dependent upregulation of short genes and downregulation of long genes (Fig. 4c), corroborating  ? ? ?
the transcriptional changes we observed from nascent RNA (Fig. 4a) and nuclear RNA from  ? ? ?
sorted nuclei (Supplementary Fig. 7a). Using the 10,390 expressed genes associated with de novo  ? ? ?
transcription by GRO-seq (Fig. 4d), we observed that genes upregulated in nascent and nuclear  ? ? ?
RNA pools are cumulatively shorter in length relative to those upregulated in whole cell RNA,  ? ? ?
and the inverse was observed among downregulated genes (Fig. 4e). Thus, gene expression  ? ? ?
changes in Mecp2 mutant neurons appear to be substantially different between subcellular  ? ? ?
compartments.  ? ? ?
 To directly compare individual genes across subcellular compartments, we next classified  ? ? ?
all 10,390 expressed genes into eight subgroups that reflect the total number of arrangements by  ? ? ?
which a gene can be misregulated across three given RNA pools (2
3
 = 8). Groups B and D  ? ? ?
comprise 38.4% of expressed genes which are involved in neuronal projection and cellular stress,  ? ? ?
respectively, and represent expression changes that are misregulated in the same direction across  ? ? ?
nascent, nuclear, and whole cell RNA pools (Fig. 4f and Supplementary Fig. 7b). Among these  ? ? ?
groups of genes, log2 fold changes measured from the whole cell are significantly smaller than  ? ? ?
that in the nuclear compartment, suggesting that gene expression changes in the nucleus are post- ? ? ?
transcriptionally minimized in the cell (Fig. 4f and Supplementary Fig. 7c). The majority of  ? ? ?
genes (48%), however, exhibit expression changes in nascent RNAs that are reversed in the  ? ? ?
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whole cell compartment (Groups A,C,G,H; Fig. 4f). Groups A and C consist of relatively long,  ? ? ?
EXC-enriched genes that are transcriptionally downregulated in nascent RNA but post- ? ? ?
transcriptionally upregulated in whole cell RNA (Fig. 4f and Supplementary Fig. 7d-e). DAVID  ? ? ?
gene ontology revealed that Group A genes are associated with synaptic functions and  ? ? ?
intracellular signaling (Fig. 4g). Groups G and H consist of considerably shorter, INH-enriched  ? ? ?
genes that are transcriptionally upregulated in nascent RNA but post-transcriptionally  ? ? ?
downregulated in whole cell RNA (Fig. 4f and Supplementary Fig. 7d-e), and Group G genes are  ? ? ?
functionally associated with cellular energy and metabolism in mitochondria (Fig. 4g). RT-PCR  ? ? ?
validation of primary and mature RNA transcripts for several genes from Groups A/C, B, and D  ? ? ?
recapitulated these apparent expression differences between subcellular compartments,  ? ? ?
particularly when genes were analyzed as a collective in their respective Group (Fig. 4h,  ? ? ?
Supplementary Fig. 8 and Supplementary Table 2). Notably, upon analyzing de novo  ? ? ?
transcriptional activity derived from GRO-seq for genes expressed in sorted excitatory or  ? ? ?
inhibitory neurons (Supplementary Fig. 7f), we found a trend towards long genes being more  ? ? ?
severely downregulated in both cell types bearing the R106W mutation than the T158M  ? ? ?
mutation (Fig. 4i and Supplementary Fig. 7g), consistent with a more severe phenotype in  ? ? ?
R106W mice.  ? ? ?
 To gain insight into the apparent switch in gene misregulation between subcellular  ? ? ?
compartments, we next used publically available HITS-CLIP datasets from the mouse brain to  ? ? ?
examine genes whose transcripts are typically bound and regulated by RNA-binding proteins  ? ? ?
(RBPs), and tested for associations with distinct subcellular gene expression changes in Mecp2  ? ? ?
mutant neurons. K-means clustering of 10,390 cortically expressed genes across HITS-CLIP data  ? ? ?
for 12 RBPs (MBNL1-2, TDP43, FUS, TAF15, FMR1, HuR, APC, RBFOX1-3, and AGO2)  ? ? ?
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identified 5 major gene clusters (Supplementary Fig. 9a). We found one subset of genes whose  ? ? ?
transcripts display significantly higher levels of HuR binding, but lower levels of AGO2 binding  ? ? ?
(RBP Clusters 1 and 4), and another subset showing significantly higher levels of AGO2 binding  ? ? ?
but lower levels of HuR binding (RBP Clusters 2, 3 and 5; Supplementary Fig. 9b-c). HuR binds  ? ? ?
to the 3UTR of mRNA transcripts (Supplementary Fig. 9d) and is known to increase mRNA  ? ? ?
stability
42
. Conversely, AGO2 functions to promote mRNA degradation through AGO2-bound  ? ? ?
miRNAs
43
. Both HuR and AGO2 genes are also actively expressed in neurons at 6-weeks of age  ? ? ?
(Supplementary Fig. 9e). By comparing gene Groups A-H, which summarize subcellular gene  ? ? ?
expression changes in Mecp2 mutant neurons (Fig. 4f), to functionally-distinct RBP clusters  ? ? ?
(Supplementary Fig. 9a-c), we found that many downregulated nascent RNA transcripts from  ? ? ?
Groups A, B, and C are significantly associated with RBP Clusters 1 and 4 and are post- ? ? ?
transcriptional targets of HuR (Supplementary Fig. 9f). By contrast, upregulated nascent RNA  ? ? ?
transcripts in Mecp2 mutant neurons, particularly from Groups G and H, show associations with  ? ? ?
RBP Clusters 2, 3, and 5, and are targets of AGO2-bound miRNAs (Supplementary Fig. 9f). The  ? ? ?
opposite functions of HuR and AGO2 in the post-transcriptional regulation of mRNA stability  ? ? ?
likely alter the abundance of cellular RNAs in a group- or cluster-specific manner. Therefore,  ? ? ?
gene expression differences between subcellular compartments in Mecp2 mutant mice could be  ? ? ?
post-transcriptionally mediated in part by RBPs (Supplementary Fig. 9g).   ? ? ?
  ? ? ?
Female RTT Mouse Models Reveal Cell and Non-Cell Autonomous DEGs: RTT is an X- ? ? ?
linked disorder that primarily affects heterozygous females. However, the extent to which  ? ? ?
intermixed Mecp2 WT and mutant (MUT) neurons in cellular mosaic RTT females affect each  ? ? ?
other at the level of gene expression remains unknown. The reduced expression level of T158M  ? ? ?
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and R106W mutant protein allowed us to use the same tagging and sorting strategy in male mice  ? ? ?
to isolate and profile WT (denoted by subscript: T158MWT, R106WWT) and MUT (T158MMUT,  ? ? ?
R106WMUT) cells from mosaic female mice. These include TAVI  ? ? ?
(Mecp2
Tavi/+
;R26
cBirA/+
;NEX
Cre/+
), T158M (Mecp2
Tavi/T158M-Tavi
;R26
cBirA/+
;NEX
Cre/+
), and R106W  ? ? ?
(Mecp2
Tavi/R106W-Tavi
;R26
cBirA/+
;NEX
Cre/+
) heterozygous females that each carry a Tavi-tagged WT  ? ? ?
allele and a Tavi-tagged T158M, R106W, or untagged WT allele. Upon aging these mice to ~18  ? ? ?
weeks, when T158M and R106W females both exhibit RTT-like phenotypes (Fig. 5a), cortical  ? ? ?
excitatory nuclei were isolated for FACS (Fig. 5b-c and Supplementary Fig. 10a). From the  ? ? ?
number of females sampled, we did not detect skewed XCI (> 75%) among excitatory neurons in  ? ? ?
TAVI, T158M, or R106W mice (Fig. 5d).  ? ? ?
 By comparing the gene expression profiles of WT or MUT neurons from heterozygous  ? ? ?
mutant mice to those from control mice (TAVIWT), a total of 526 and 678 unique protein-coding  ? ? ?
DEGs in T158MWT and MUT and R106WWT and MUT neurons were identified, respectively (Fig. 5e,  ? ? ?
Supplementary Fig. 10b and Table 1). Most DEGs represent cell autonomous gene expression  ? ? ?
changes that occur in mutant neurons alone (Fig. 5e). However, a larger proportion of R106W  ? ? ?
DEGs are also found in R106WWT neurons (43.4%; Fig. 5e), revealing a mutation-specific  ? ? ?
susceptibility of WT neurons to non-cell autonomous gene expression changes in heterozygous  ? ? ?
females. Using principal component analysis (PCA) to plot the first two major axes of  ? ? ?
transcriptome variation, we found that PC2 separates neuronal populations by Mecp2 allele  ? ? ?
status (WT vs. MUT neurons) irrespective of the T158M or R106W mutation (Fig. 5f),  ? ? ?
indicating that Mecp2 mutations induce cell autonomous changes that are transcriptionally  ? ? ?
distinct from neighboring wild-type neurons. However, PC1 accounts for nearly twice the  ? ? ?
variation as PC2 and clusters R106WWT and MUT populations away from other genotypes, likely  ? ? ?
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due to the extensive number of indirect DEGs associated with this mutation. In contrast, against  ? ? ?
PC1 and PC2, T158MWT neurons closely resemble TAVIWT (Fig. 5f), indicating that the non-cell  ? ? ?
autonomous DEGs observed in R106WWT neurons specifically arise due to the increased severity  ? ? ?
of R106W mutation in R106WMUT neurons.  ? ? ?
We further found 194 DEGs that overlap between T158M and R106W female mice, most  ? ? ?
of which are misregulated in the same direction (Fig. 5g). Among these genes, cell autonomous  ? ? ?
transcriptional changes (149 genes, 76.8%) are more likely to be shared across independent  ? ? ?
Mecp2 mutations than non-cell autonomous changes (9 genes, 4.6%; Fig. 5h). These overlapping  ? ? ?
DEGs also show higher fold changes in R106W than T158M female mice, but this difference is  ? ? ?
mainly driven by indirect DEGs in R106W neurons (Fig. 5i).  ? ? ?
In R106W female mice, we found that non-cell autonomous DEGs are predominantly  ? ? ?
upregulated (~60%) in contrast to cell autonomous DEGs (~48%; Supplementary Fig. 10b), and  ? ? ?
display significantly higher fold changes than cell autonomous DEGs (Supplementary Fig. 10c).  ? ? ?
Furthermore, cell autonomous DEGs are considerably longer in gene length, specifically among  ? ? ?
upregulated genes (Supplementary Fig. 10d). To determine if cell and non-cell autonomous  ? ? ?
DEGs represent distinct biological processes, we also performed pre-ranked GSEA (FDR < 0.1)  ? ? ?
and found that non-cell autonomous gene expression changes primarily affect cell-to-cell  ? ? ?
signaling and negative regulation of protein phosphorylation (Supplementary Fig. 10e). These  ? ? ?
DEGs include several immediate early and late response genes that are induced by neuronal  ? ? ?
activity and modulate signaling pathways associated with synaptic plasticity
44
. In contrast, cell  ? ? ?
autonomous DEGs are significantly associated with transcriptional regulation (Supplementary  ? ? ?
Fig. 10f). These functional categories demonstrate a marked resemblance to those observed in  ? ? ?
excitatory neurons of male T158M and R106W mice (Fig. 5j). The striking consistency with  ? ? ?
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which these functional annotations characterize Mecp2 mutant neurons, despite apparent  ? ? ?
differences in age and sex, supports the cell autonomous disruption of these functions as a key,  ? ? ?
contributing factor to RTT pathogenesis.  ? ? ?
  ? ? ?
Discussion: The complexity of MeCP2 molecular function, coupled with the cellular  ? ? ?
heterogeneity of the brain, confounds the study of transcriptional changes in RTT. We thus  ? ? ?
combined in vivo biotinylation with Cre-Lox technology to label both wild-type and mutant  ? ? ?
MeCP2 from different neuronal populations and examined RTT-associated transcriptomes in  ? ? ?
mice. Notably, the 23AA Tavi tag can be readily used to target any given protein using CRISPR- ? ? ?
Cas9 technology
45
 for cell type-specific biochemical purifications, molecular profiling, and  ? ? ?
imaging applications.   ? ? ?
By using an allelic series of RTT mutations to perform a transcriptome analysis of  ? ? ?
cortical neurons, we identified similarities and differences in gene expression features that  ? ? ?
couple impairments in MeCP2s ability to bind DNA to RTT phenotypic severity. We found that  ? ? ?
lowly-expressed, cell type-enriched genes are sensitive to the effects of both T158M and R106W  ? ? ?
mutations, which likely contributes to the specificity of MeCP2-mediated gene expression  ? ? ?
changes among different neuronal cell types. Both mutations also display conserved  ? ? ?
transcriptional features among upregulated DEGs in male and female neurons, which include  ? ? ?
genes encoding INH-enriched transcription factors and chromatin remodelers. The upregulation  ? ? ?
of transcriptional regulators could contribute to the shared RTT etiology between T158M and  ? ? ?
R106W mice, as well as the genome-wide trend towards increased transcription of shorter, INH- ? ? ?
enriched genes associated with cellular respiration and energy metabolism. This provides  ? ? ?
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transcriptional insight into clinical features among both mildly and severely affected RTT  ? ? ?
patients that resemble mitochondrial and metabolic disorders
46
.  ? ? ?
However, the greater impairment in MeCP2 R106W binding to neuronal chromatin  ? ? ?
associates with increased RTT phenotypic severity, and notably correlates with the larger  ? ? ?
number and degree of misregulated genes that are more highly expressed and predominately  ? ? ?
downregulated relative to the T158M mutation. These transcriptional differences extend to most  ? ? ?
long genes throughout the genome, which are highly expressed in neurons
47
. Our datasets are in  ? ? ?
partial agreement with global reductions in Ser5-phosphorylated RNA polymerase in Mecp2-null  ? ? ?
neuronal nuclei
48
, supporting MeCP2 as a global modulator of gene transcription. Loss of  ? ? ?
MeCP2 occupancy may either alter local chromatin organization, which could decrease the  ? ? ?
efficiency of transcriptional elongation
49
 and lead to the downregulation of long genes, or may  ? ? ?
abrogate HDAC3-mediated recruitment of transcription factors required for long gene  ? ? ?
transcriptional activation
50
. Because downregulated genes associate with synaptic morphology  ? ? ?
and function, and R106W mice have reduced lifespans compared to T158M mice, reductions in  ? ? ?
long gene transcription may act as modifiers to worsen RTT-like phenotypes. RTT patients with  ? ? ?
mutations that preserve MeCP2 binding do exhibit milder features than patients for whom  ? ? ?
binding is disrupted
12
. Transcriptional assessments with mutations preserving MeCP2 binding  ? ? ?
are thus necessary to further refine these genotype-phenotype correlations.  ? ? ?
Because MeCP2 is a DNA-binding nuclear protein
22
, nuclear and nascent RNA pools  ? ? ?
provide additional insights into the primary effects of RTT mutations on transcriptional  ? ? ?
activity
37,38,51
 that complement the reported whole cell upregulation of long genes in RTT
27,39
.  ? ? ?
Whole cell RNA is subject to post-transcriptional regulation
40,52,53
, being notably enriched for  ? ? ?
cytoplasmic mRNAs that are bound by various RBPs to modulate their steady-state abundance  ? ? ?
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and turnover. We found that many downregulated nascent RNA transcripts are targets of HuR,  ? ? ?
which increases mRNA stability in the brain
42
 and may post-transcriptionally upregulate these  ? ? ?
transcripts in whole cell RNA. Upregulated nascent RNA transcripts tend to associate with  ? ? ?
miRNA-bound AGO2, which may post-transcriptionally mitigate their upregulation by  ? ? ?
increasing rates of mRNA decay
43
. These post-transcriptional mechanisms may abate cellular  ? ? ?
consequences arising from global alterations in synaptic, mitochondrial, and metabolic gene  ? ? ?
transcription. Whole cell gene expression changes in RTT may thus be compensatory and not  ? ? ?
entirely representative of transcriptional activity, questioning the therapeutic benefit of  ? ? ?
decreasing long gene transcription for treating RTT.  Identifying RBPs that contribute to cellular  ? ? ?
compensation may yield a novel class of interventional therapies administered prior to or during  ? ? ?
the initial phases of RTT, minimizing its pathological impact.  ? ? ?
Finally, our approach allows for the molecular profiling of mosaic neurons from female  ? ? ?
mice that represent accurate preclinical RTT models, revealing non-cell autonomous changes in  ? ? ?
WT neurons that depend on mutation severity. However, to better elucidate direct and indirect  ? ? ?
contributions to RTT, further investigation requires examination of females with a wide range of  ? ? ?
XCI ratios across multiple ages, cell types, and Mecp2 mutations. Non-cell autonomous DEGs  ? ? ?
include genes induced by neuronal activity to reduce synaptic responsiveness to excessive  ? ? ?
neuronal stimuli
44
. Nuclear RNA transcripts of two late-response genes in particular, Bdnf and  ? ? ?
Igf1, were found to be transcriptionally upregulated in WT and MUT neuronal nuclei of 18-week  ? ? ?
old R106W female mice. As Bdnf and Igf1 encode neuroprotective peptides that ameliorate RTT  ? ? ?
symptoms
20
, the selective upregulation of non-cell autonomous DEGs in R106W mice may be a  ? ? ?
protective response to increased neuronal activity or stress among severely affected mosaic  ? ? ?
neurons. Currently, BDNF and IGF-1 peptides are being tested in clinical trials
54,55
. Further study  ? ? ?
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of molecular pathways associated with non-cell autonomous DEGs may thus reveal additional  ? ? ?
RTT therapeutic targets and avenues.  ? ? ?
  ? ? ?
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Figure 1. Utilization and characterization of Mecp2
Tavi
 mice and associated RTT variants. (a)  ? ? ?
Diagram of wild-type and tagged MeCP2 showing R106W or T158M missense mutations. MBD,  ? ? ?
Methyl-CpG Binding Domain; TRD, Transcriptional Repression Domain. (b) Breeding strategy  ? ? ?
to biotinylate the Tavi tag in a Cre-dependent manner. (c) Representative western blot showing  ? ? ?
the conditions in which the Tavi tag is biotinylated using whole brain nuclear extracts. Blot is  ? ? ?
probed with streptavidin for biotin detection and antibodies against MeCP2 N-terminus, Tavi tag,  ? ? ?
and NeuN. (d) Representative images showing immunofluorescent detection of biotinylated  ? ? ?
MeCP2 and mutant variants in hippocampal sections of untagged (WT) and tagged (TAVI,  ? ? ?
T158M, R106W) male mice at 6 weeks of age. Tissue is probed with streptavidin for biotin  ? ? ?
detection and antibody against the MeCP2 C-terminus. Scale bars represent 10 µm. (e)  ? ? ?
Quantification and representative western blot comparing MeCP2 protein expression levels  ? ? ?
between TAVI and mutant (T158M, R106W) male mice at 6 weeks of age. Blot is probed with  ? ? ?
antibodies against the MeCP2 C-terminus and TBP (nreplicates = 3, One-way ANOVA). (f)  ? ? ?
Quantification of salt-extracted MeCP2 from chromatin using 200mM (left) and 400mM (right)  ? ? ?
NaCl, normalized to extracts using 500mM NaCl (see Supplemental Fig. 2e; nreplicates = 4-5, One- ? ? ?
way ANOVA). (g) Box-and-whisker plot of brain weights from untagged (WT, KO (Mecp2- ? ? ?
null)) and tagged (TAVI, T158M, R106W) male mice at 6 weeks of age (nWT = 20, nTAVI = 11,  ? ? ?
nKO = 6, nT158M = 6, nR106W = 12; One-way ANOVA). Box limits denote 25
th
 and 75
th
 percentiles,  ? ? ?
center line denotes median, + denotes mean, and whiskers denote data max and min. Each  ? ? ?
genotype is indicated with a different color. (h) Body weight over postnatal age in untagged  ? ? ?
(WT, KO) and tagged (TAVI, T158M, R106W) male mice. Data points consist of at least 6  ? ? ?
observations each. Total number of mice assessed: nWT = 31, nTAVI = 23, nKO = 15, nT158M = 14,  ? ? ?
nR106W = 28. (i) RTT-like phenotypic score across postnatal development in untagged (WT, KO)  ? ? ?
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and tagged (TAVI, T158M, R106W) male mice. Data points over time consist of at least 6  ? ? ?
observations each. Total number of mice assessed: nWT = 31, nTAVI = 23, nKO = 15, nT158M = 14,  ? ? ?
nR106W = 28. (j) Kaplan-Meier survival curve for untagged (WT, KO) and tagged (TAVI,  ? ? ?
T158M, R106W) male mice (nWT = 31, nTAVI = 23, nKO = 17, nT158M = 39, nR106W = 26). *P < 0.5,  ? ? ?
**P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant; all pooled data depicts mean ±  ? ? ?
SEM unless otherwise stated. See also Supplementary Figs. 1 and 2.  ? ? ?
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Figure 2. Cell type-specific transcriptional profiling of neuronal nuclei. (a) Representative  ? ? ?
images showing immunofluorescent detection of biotinylated MeCP2-Tavi protein in Cre- ? ? ?
specified neuronal populations of the mouse hippocampus. Probed using streptavidin for biotin  ? ? ?
detection and antibody against the MeCP2 C-terminus. Scale bars represent 100µm. (b)  ? ? ?
Schematic of cortical nuclei preparation and FACS isolation. (c) FACS analysis of labeled  ? ? ?
cortical nuclei populations. Data shown is representative of nine independent experiments using  ? ? ?
NEX-Cre mice. Percentages indicate the mean distribution of neurons that are NeuN+Biotin+  ? ? ?
(excitatory; 85.2% ± 0.35) or NeuN+Biotin- (inhibitory; 14.8% ± 0.35). (d) RT-PCR validation  ? ? ?
of FACS-isolated populations depicted in (c) (nreplicates = 3, Two-way ANOVA). (e) Pearson  ? ? ?
correlation of biological replicate nuclear RNA-seq libraries within (intra-replicate) and across  ? ? ?
(inter-replicate) FACS-isolated populations depicted in (c). Colors correspond to EXC-enriched  ? ? ?
(blue) and INH-enriched (red) genes identified through differential expression analysis of  ? ? ?
excitatory and inhibitory neurons. Note lower Pearson correlation and clear dispersal of cell  ? ? ?
type-enriched genes across FACS populations. (f) IGV browser snapshot of Dlgap1 genomic  ? ? ?
locus in excitatory and inhibitory neurons of TAVI male mice at 6 weeks of age. RefSeq and  ? ? ?
Ensembl gene annotations are both shown. *P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001,  ? ? ?
n.s. = not significant; all pooled data depicts mean ± SEM. See also Supplementary Figs. 3 and  ? ? ?
4.  ? ? ?
  ? ? ?
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Figure 3. Analysis of T158M and R106W differentially expressed genes. (a) FACS isolation of  ? ? ?
cortical excitatory and inhibitory neuronal nuclei from TAVI, T158M, or R106W male mice at 6  ? ? ?
weeks of age. (b) Total number of protein coding and non-coding differentially expressed genes  ? ? ?
(DEGs) identified in excitatory or inhibitory neurons of Mecp2 mutant mice. (c) Heatmaps  ? ? ?
display log2 fold changes among protein-coding DEGs in excitatory and inhibitory neurons of  ? ? ?
Mecp2 mutant mice, compared across genotypes. Excitatory DEGs nshared = 69 genes,  ? ? ?
Hypergeometric P = 3.15e
-77
. Inhibitory DEGs nshared = 107 genes, Hypergeometric P = 5.33e
-134
.  ? ? ?
Boxplots compare log2 median fold changes among overlapping DEGs between T158M and  ? ? ?
R106W neurons (One-tailed Wilcoxon Signed Rank). (d) Heatmap displaying log2 fold changes  ? ? ?
among protein-coding DEGs in excitatory and inhibitory neurons of Mecp2 mutant mice,  ? ? ?
compared across cell types. (e) Left graph, Distribution of constitutive, EXC- or INH-enriched  ? ? ?
genes among T158M and R106W protein-coding DEGs, compared against genomic distribution  ? ? ?
(Chi-square Goodness-of-Fit). Right graph, Bar plot summarizing R106W DEGs in excitatory  ? ? ?
neurons, partitioned by cell type-enriched or constitutive genes, and which are preferentially  ? ? ?
upregulated or downregulated. Red indicates statistical significance (One-tailed Fishers Exact  ? ? ?
Test). (f) Enrichment map of pre-ranked Gene Set Enrichment Analysis (GSEA) functional  ? ? ?
network associations. Data represents DEGs from R106W (top) and T158M (bottom) excitatory  ? ? ?
neurons (P-value < 0.01, Q-value < 0.1). Nodes denote functional categories, colored by  ? ? ?
Normalized Enrichment Score (NES). Line weight denotes extent of gene overlap between  ? ? ?
connected nodes. Red text highlights the similarity in functional annotations between both  ? ? ?
genotypes. (g) Boxplots comparing the log2 FPKM distribution of actively expressed genes  ? ? ?
against T158M, R106W, and shared DEGs for each cell type (Pairwise Wilcoxon Rank Sum P  ? ? ?
 32
displayed). *P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant. See also  ? ? ?
Supplementary Figs. 5 and 6. ? ? ?
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  ? ? ?
Figure 4. Genome-wide length-dependent transcriptional changes in RTT mutant mice. (a)  ? ? ?
Genome-wide log2 fold changes in R106W mice (n = 2) compared to TAVI mice (n = 2) at 6  ? ? ?
weeks of age using GRO-seq. Top, Lines represent mean fold change in expression for genes  ? ? ?
binned according to gene length (200 gene bins, 40 gene step) as described in
27
. Ribbon  ? ? ?
represents SEM of genes in each bin. Bottom, Smoothed scatterplot depicting LOESS correlation  ? ? ?
between gene length and log2 fold change for all individual protein-coding genes detected in  ? ? ?
GROseq. Genes in red highlight R106W DEGs identified from sorted excitatory and inhibitory  ? ? ?
neuronal nuclei. (b,c) Same as in (a), but using total RNA-seq analysis of whole cell (b) or  ? ? ?
nuclear (c) RNA isolated from left or right cortex of the same mice at 6 weeks of age (n=2). (d)  ? ? ?
Top, Diagram of RNA distribution across subcellular compartments. Bottom, Area proportional  ? ? ?
Venn diagram comparing overlap in gene expression changes between nuclear RNA, whole cell  ? ? ?
RNA, and nascent RNA. (e) Cumulative distribution function of gene lengths for all upregulated  ? ? ?
and downregulated protein-coding genes among nascent, nuclear, and whole cell RNA pools (n =  ? ? ?
10,390 genes, Kolmogorov-Smirnov). (f) Top, Boxplots depicting median log2 fold changes in  ? ? ?
R106W mice between nascent, nuclear, and whole cell RNA pools, classified by the direction of  ? ? ?
gene misregulation (n = 10, 390 genes, Pairwise Wilcoxon Rank Sum P displayed). Gene groups  ? ? ?
are arranged by median gene length (black bar on top). Arrows highlight the percentage of  ? ? ?
10,390 genes that display similar (38.4% of expressed genes), opposite (48%), or dynamic  ? ? ?
changes (13.6%) across subcellular RNA pools. Bottom, Heatmap displaying statistical  ? ? ?
enrichment of T158M and R106W DEGs in excitatory neurons among gene groups (One-tailed  ? ? ?
Fishers Exact Test). (g) DAVID Gene ontology terms (Benjamini P < 0.01, FDR < 0.05) for  ? ? ?
Group A and Group G sets of genes defined in (f). (h) Top, Diagram of RT-PCR primer design  ? ? ?
to measure mature and primary RNA transcripts. Bottom, Data shows overall trend in gene  ? ? ?
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expression mean fold changes using primers against primary and mature RNA transcripts (left)  ? ? ?
or primary transcripts only (right)_across individual genes from Group A/C (n = 7 genes), Group  ? ? ?
B (n = 5 genes), and Group D (n = 5 genes) in R106W compared to TAVI mice (Two-way  ? ? ?
ANOVA). Data depicts mean ± S.D. (i) Mean log2 fold change in 6-week R106W (red; n = 4)  ? ? ?
and T158M (orange, n = 4) sorted excitatory (left) and inhibitory neurons (right) using genes that  ? ? ?
are also detected in GRO-seq. *P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not  ? ? ?
significant. See also Supplementary Figs. 7-9.   ? ? ?
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  ? ? ?
Figure 5. T158M and R106W differentially expressed genes in mosaic female mice. (a) RTT- ? ? ?
like phenotypic score in TAVI (n = 12), T158M (n = 4), and R106W (n = 9) heterozygous  ? ? ?
female mice (Two-way ANOVA). Data depicts mean ± SEM. (b) FACS isolation of excitatory  ? ? ?
neuronal nuclei from the cortex of heterozygous TAVI, T158M, or R106W female mice. (c)  ? ? ?
Biotin signal intensity from FACS-isolated populations depicted in (b) (nT158M = 4, nR106W = 9,  ? ? ?
Two-way ANOVA). Data depicts mean ± SEM. (d) X-inactivation ratios among cortical  ? ? ?
excitatory neurons in all sorted female mice, displayed as a percentage of the FACS-sorted WT  ? ? ?
population (nTAVI = 12, nT158M = 4, nR106W = 9, One-way ANOVA). Data points in red indicate  ? ? ?
samples used for RNA-seq. Data depicts mean ± SEM. (e) Bar graph showing the cell and non- ? ? ?
cell autonomous distribution of total protein-coding DEGs identified from T158M and R106W  ? ? ?
female mice. (f) Principal component analysis of WT and MUT cell populations isolated from  ? ? ?
TAVI, T158M, and R106W female mice. (g) Heatmap displaying log2 fold changes among the  ? ? ?
total number of protein-coding DEGs detected in both WT and MUT populations from T158M  ? ? ?
or R106W female mice. Note genes that overlap across genotype (n = 194). (h) Proportion of cell  ? ? ?
autonomous (CA) and non-cell autonomous (NCA) genes that overlap between T158M and  ? ? ?
R106W female excitatory neurons (One-tailed Fishers Exact Test). (i) Boxplots comparing  ? ? ?
absolute log2 fold change between cell autonomous and non-cell autonomous shared DEGs (n =  ? ? ?
185) between T158M and R106W female mice (One-tailed Wilcoxon Signed Rank). (j)  ? ? ?
Enrichment map of pre-ranked GSEA functional network associations (P-value < 0.01, Q-value  ? ? ?
< 0.1). Data represents DEGs that overlap between T158M and R106W mice (n = 185). Nodes  ? ? ?
denote functional categories, colored by Normalized Enrichment Score (NES). Line weight  ? ? ?
denotes extent of gene overlap between connected nodes. *P < 0.5, **P < 0.01, ***P < 0.001,  ? ? ?
****P < 0.0001, n.s. = not significant. See also Supplementary Fig. 10.  ? ? ?
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Experiment Cell Type Genotype 
Differentially Expressed Genes 
(DEGs) 
Upregulated/ 
Downregulated 
(Protein-coding) 
|Log2 Fold Change| Gene Length (kb) Proportion of Cell Type Enriched Genes 
(Protein-coding) 
(Protein-coding) (Protein-coding) 
Total Coding 
Non-
coding 
Median [IQR] Median [IQR] Constitutive 
Excitatory 
(EXC) 
Inhibitory 
(INH) 
6 WEEK 
Males 
Actively Expressed 
Genes 
Excitatory Neurons TAVI (Control) 13877 10926 2951 - - 24.9 [9.9 - 61.3] 46.5% 28.5% 24.9% 
Inhibitory Neurons TAVI (Control) 10369 8319 2050 - - 25.4 [10.3 - 61.5] 46.8% 24.3% 28.8% 
Cell Type-enriched 
Gene Expression 
Excitatory Neurons TAVI (Control) 4593 3958 635 - 0.75 [0.41 - 1.46] 50.6 [21.5 - 110.1] - 100% - 
Inhibitory Neurons TAVI (Control) 4783 4194 589 - 0.73 [0.45 - 1.47] 21.2 [8.8 - 53.0] - - 100% 
MeCP2-dependent 
Gene Expression 
Excitatory Neurons 
T158M 197 177 20 63.8% DOWN 0.45 [0.33 - 0.62] 88.6 [33.5 - 173.1] 16.4% 49.2% 34.5% 
R106W 425 386 39 61.7% DOWN 0.44 [0.34 - 0.61] 82.5 [36.7 - 146.0] 17.6% 51.3% 31.1% 
Shared DEGs 75 69 6 65.2% DOWN see Figure 3D 109.8 [49.9 - 184.1] 14.5% 52.2% 33.3% 
Inhibitory Neurons 
T158M 146 143 3 62.9% UP 0.45 [0.29 - 0.55] 107.8 [41.4 - 188.7] 20.3% 44.8% 35.0% 
R106W 758 697 61 56.2% UP 0.41 [0.33 - 0.56] 40.5 [19.1 - 102.9] 29.4% 35.3% 35.3% 
Shared DEGs 109 107 2 64.5% UP see Figure 3D 112.8 [42.9 - 202.8] 18.7% 46.7% 34.6% 
18 
WEEK 
Females 
MeCP2-dependent 
Gene Expression 
Excitatory Neurons 
T158MWT 42 28 14 64.3% DOWN 0.52 [0.49 - 0.79] 54.6 [27.2 - 112.6] - - - 
R106WWT 346 294 52 62.2% UP 0.64 [0.47 - 0.93] 51.4 [21.0 - 140.4] - - - 
T158MMUT 585 516 69 67.2% DOWN 0.49 [0.40 - 0.73] 51.2[20.4 - 113.2] - - - 
R106WMUT 634 569 65 52.2% UP 0.54 [0.43 - 0.83] 65 [31.7 - 142.1] - - - 
SharedMUT 207 185 22 65.9% DOWN see Figure 5I 77.5 [36.2 - 143.6] - - - 
  ? ? ?
Table 1 Summary of Differentially Expressed Genes (DEGs) identified in the study  ? ? ?
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Online Methods  ? ? ?
Generation of Mouse Lines The targeting construct used for homologous recombination at the  ? ? ?
Mecp2 locus in murine ES cells was cloned in two arms by PCR amplification of sv129 genomic  ? ? ?
DNA. The 5͛ arm was PCR amplified with 5͛-AGGAGGTAGGTGGCATCCTT-3͛ and 5͛ ? ? ?
-CGTTTGATCACCATGACCTG-3͛ primers, whereas the 3͛ arm was PCR amplified with 5 ? ? ?
͛-GAAATGGCTTCCCAAAAAGG-3͛ and 5͛-AAAACGGCACCCAAAGTG-3͛ primers.  ? ? ?
Restriction sites at the ends of each arm were created using nested primers for cloning into a  ? ? ?
vector containing a loxP-flanked neomycin cassette (Neo) and a diphtheria toxin A negative- ? ? ?
selection cassette. QuikChange (Stratagene) insertional mutagenesis was used to generate the  ? ? ?
Mecp2
Tavi
 targeting construct by inserting the Tavi tag immediately upstream of the Mecp2 stop  ? ? ?
codon within the 5 arm. The portion of the Tavi tag containing the biotinylation consensus  ? ? ?
sequenced flanked by 5 NaeI and 3 BspHI restriction sites was inserted through two rounds of  ? ? ?
mutagenesis:  ? ? ?
  ? ? ?
Round 1 Forward: 5- ? ? ?
GACCGAGAGAGTTAGCGCCGGCCTGAACGACATCTTCGAGTCATGACTTTACATAG ? ? ?
AGCG-3  ? ? ?
Round 1 Reverse: 5- ? ? ?
CGCTCTATGTAAAGTCATGACTCGAAGATGTCGTTCAGGCCGGCGCTAACTCTCTCG ? ? ?
GTC-3  ? ? ?
  ? ? ?
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Round 2 Forward: 5- ? ? ?
CTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAATCATGACTTTACATA ? ? ?
GAG-3  ? ? ?
Round 2 Reverse: 5- ? ? ?
CTCTATGTAAAGTCATGATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTC ? ? ?
AG-3  ? ? ?
  ? ? ?
The portion of the tag containing the TEV protease cleavage site was inserted upstream of the  ? ? ?
NaeI restriction site with a third round of mutagenesis:  ? ? ?
  ? ? ?
Round 3 Forward: 5- ? ? ?
GACCGAGAGAGTTAGCGAAAACCTGTATTTTCAGGGCGCCGGCCTGAACGACATC-3  ? ? ?
Round 3 Reverse: 5-  ? ? ?
GATGTCGTTCAGGCCGGCGCCCTGAAAATACAGGTTTTCGCTAACTCTCTCGGTC-3  ? ? ?
  ? ? ?
To generate Mecp2
Tavi
 targeting constructs bearing independent RTT-associated point  ? ? ?
mutations, QuikChange site-directed mutagenesis was used to mutate MeCP2 arginine 106 to  ? ? ?
tryptophan and MeCP2 threonine 158 to methionine within the 3arm and 5arm, respectively. A  ? ? ?
single nucleotide at codon T160 also underwent site-directed mutagenesis for a silent mutation to  ? ? ?
introduce a BstEII restriction site to correctly identify targeted ES cells.  ? ? ?
To generate conditional R26
cBirA
 transgenic mice, PCR primers containing AscI  ? ? ?
restriction sites and a Kozak consensus sequence were used to subclone the BirA coding  ? ? ?
sequence and insert it downstream of both a CAG promoter and a floxed transcriptional  ? ? ?
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attenuator, Neo-STOP, within pROSA26-1, a transgenic targeting vector that has previously been  ? ? ?
characterized
56
.  ? ? ?
After confirmation by Sanger sequencing and linearization with NotI (Mecp2
Tavi
 targeting  ? ? ?
construct and its mutant variants) or SgfI (cBirA targeting construct), the constructs were  ? ? ?
electroporated into sv129-derived murine ES cells. Correctly targeted ES cells were  ? ? ?
independently injected into C57BL/6 blastocysts and subsequently implanted into  ? ? ?
pseudopregnant females. Agouti offspring were screened by southern blot and PCR genotyping  ? ? ?
to confirm germline transmission of the Mecp2
Tavi
, Mecp2
T158M-Tavi
, Mecp2
R106W-Tavi
, and R26
cBirA
  ? ? ?
alleles. In the case of the Mecp2
Tavi
 allele and its mutant variants, the resulting offspring were  ? ? ?
mated with C57BL/6 EIIa-cre mice to ensure germline deletion of the floxed Neo cassette  ? ? ?
between Mecp2 exons 3 and 4.  ? ? ?
  ? ? ?
Additional Mouse lines Dlx5/6-Cre (Stock #008199) and EIIa-Cre (Stock #003724) mice were  ? ? ?
obtained from The Jackson Laboratory (Bar Harbor, ME)
31,36
. NeuroD6/NEX-Cre mice were  ? ? ?
obtained with permission from the Nave Laboratory
35
.  ? ? ?
  ? ? ?
Animal Husbandry Experiments were conducted in accordance with the ethical guidelines of  ? ? ?
the US National Institutes of Health and with the approval of the Institutional Animal Care and  ? ? ?
Use Committee of the University of Pennsylvania. All of the experiments described were  ? ? ?
performed using mice on a congenic sv129:C57BL/6J background with the knock-in/transgenic  ? ? ?
alleles backcrossed to C57BL/6J mice (The Jackson Laboratory) for at least five generations,  ? ? ?
unless otherwise stated. Mice were housed in a standard 12h light/12h dark cycle with access to  ? ? ?
ample amounts of food and water. Mice bearing the Tavi tag were genotyped using a bipartite  ? ? ?
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primer PCR-based strategy to detect the Tavi tag at the 3-end of the endogenous Mecp2 gene  ? ? ?
(Forward: 5-CACCCCGAAGCCACGAAACTC-3, Reverse: 5- ? ? ?
TAAGACTCAGCCTATGGTCGCC-3) and give rise to a 318-bp product from the wild-type  ? ? ?
allele and a 388-bp product from the tagged allele. Mice bearing the BirA transgene were  ? ? ?
genotyped using a tripartite primer PCR-based strategy to detect the presence or absence of the  ? ? ?
CAG promoter at the Rosa26 locus (Forward:5-TGCTGCCTCCTGGCTTCTGAG-3, Reverse  ? ? ?
#1: 5-GGCGTACTTGGCATATGATACAC-3, Reverse #2: 5- ? ? ?
CACCTGTTCAATTCCCCTGCAG-3) and give rise to a 173-bp product from the wild-type  ? ? ?
allele and a 477-bp product from the transgene-bearing allele. Mice bearing Cre-recombinase  ? ? ?
(either NeuroD6/NEX-Cre or Dlx5/6-Cre) were genotyped using PCR-based strategies as  ? ? ?
previously described
35,36
.  ? ? ?
  ? ? ?
Phenotypic Assessment For tagged Mecp2 knock-in mice, phenotypic scoring was performed  ? ? ?
on a weekly basis for the presence or absence of overt RTT-like symptoms as previously  ? ? ?
described
33
. Investigator was blinded to genotypes during phenotypic assessment of mice. For  ? ? ?
BirA transgenic mice, no formal scoring was performed. However, R26
BirA
 heterozygous and  ? ? ?
homozygous mice are viable, fertile, and devoid of any gross abnormalities, consistent with  ? ? ?
previously engineered transgenic mice that express BirA either ubiquitously or within restricted  ? ? ?
tissues using cell type-specific promoters
57,58
.  ? ? ?
  ? ? ?
Immunofluorescence and Microscopy Mice were anesthetized with 1.25% Avertin (wt/vol),  ? ? ?
transcardially perfused with 4% paraformaldehyde (wt/vol) in 0.1M sodium-potassium  ? ? ?
phosphate buffered saline and postfixed overnight at 4°C. Brains were coronally or sagittally  ? ? ?
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sectioned at 20µm using a Leica CM3050 S cryostat. Immunofluorescence on free-floating  ? ? ?
sections was performed as previously described
18
, except sections were permeabilized with 0.5%  ? ? ?
Triton without methanol for 20 minutes, and sections were blocked overnight with 10% Normal  ? ? ?
Goat Serum and 1:100 unconjugated goat anti-mouse IgG (Sigma M5899). The following  ? ? ?
primary antibodies were incubated at 4°C overnight: rabbit anti-MeCP2 C-terminus (1:1000, in  ? ? ?
house), rabbit anti-nucleolin (1:1000, Abcam ab22758), mouse anti-parvalbumin (1:500,  ? ? ?
Millipore MAB1572), rabbit anti-calretinin (1:1000, Swant 7699/3H), mouse anti-GAD67  ? ? ?
(1:500, Millipore MAB5406), mouse anti-NeuN (1:500, Millipore MAB377). For rat anti- ? ? ?
somatostatin (1:250, Millipore MAB354MI), primary incubation was performed for 48 hours at  ? ? ?
4°C. Fluorescence detection of primary antibodies was performed using Alexa 488-conjugated  ? ? ?
goat anti-rabbit (1:1000, Invitrogen A11008), Alexa 488-conjugated goat anti-mouse (1:1000,  ? ? ?
Invitrogen A11029), or Alexa 488 goat anti-rat (1:1000, Invitrogen A11006). Fluorescence  ? ? ?
detection of biotin was performed simultaneously with Streptavidin Dylight 650 (1:1000, Fisher  ? ? ?
84547) for fluorescence microscopy and Streptavidin Dylight 550 (1:1000, Fisher 84542) for  ? ? ?
confocal microscopy. Sections were counterstained with DAPI (1:1000, Affymetrix 14564) to  ? ? ?
visualize DNA before mounting with Fluoromount G (SouthernBiotech). Images were acquired  ? ? ?
using a Leica DM5500B fluorescent microscope with a Leica DFC360 FX digital camera  ? ? ?
(region-specific biotinylation, quantification of neuronal cell type-specific markers) or a Leica  ? ? ?
TCS SP8 Multiphoton confocal microscope (representative images of neuronal cell type specific  ? ? ?
markers, subcellular localization of MeCP2). Images were acquired using identical settings for  ? ? ?
laser power, detector gain amplifier offset and pinhole diameter in each channel. Image  ? ? ?
processing was performed using ImageJ and Adobe Photoshop, including identical adjustments  ? ? ?
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of brightness, contrast, and levels in individual color channels and merged images across  ? ? ?
genotypes.  ? ? ?
  ? ? ?
Quantitative Western analysis Quantitative Western blot was performed using Odyssey  ? ? ?
Infrared Imaging System (Licor). Primary antibodies used in this study include rabbit anti- ? ? ?
MeCP2 C-terminus (1:4000, in house), mouse anti-MeCP2 N-terminus (1:4000, Sigma M7433),  ? ? ?
mouse anti-NeuN (1:500, Millipore MAB377), rabbit anti-Avi tag (1:5000, Abcam ab106159,  ? ? ?
listed as anti-Tavi in main text, detects the minimal peptide substrate of biotin ligase BirA  ? ? ?
regardless of biotinylation status), rabbit anti-HDAC3 (1:1000, Santa Cruz sc-11417), rabbit  ? ? ?
anti-TBLR1 (1:1000, Bethyl A300-408A), rabbit anti-Sin3A, (1:500, Thermo Scientific PA1- ? ? ?
870), rabbit anti-Histone H3 (1:1000, Abcam ab1791), and rabbit anti-TBP (1:1000, Cell  ? ? ?
Signaling #8515). Secondary antibodies include anti-rabbit IRDye 680LT (1:10,000, Licor), anti- ? ? ?
mouse IRDye 800CW (Licor), Streptavidin Dylight 650 (1:10,000, Fisher 84547) and  ? ? ?
Streptavidin Dylight 800 (1:10,000, Fisher 21851). Quantification of protein expression levels  ? ? ?
was carried out following Odyssey Infrared Imaging System protocols. Scans of full-length  ? ? ?
Western blot membranes are provided in Supplementary Figs. 11-13.  ? ? ?
  ? ? ?
Co-immunoprecipitation using nuclear extracts Tissues were mined on ice and homogenized  ? ? ?
in ice cold lysis buffer (10 mM HEPES pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5% NP-40, 0.2mM  ? ? ?
EDTA, protease inhibitors). Nuclei were pelleted, washed and resuspended in nuclear extract  ? ? ?
(NE) buffer (20mM HEPES pH 7.9, 1.5mM MgCl2, 500mM KCl, 0.2mM EDTA, 10% glycerol,  ? ? ?
protease inhibitors). Nuclei were incubated in NE buffer at 4°C for two hours with rotation.  ? ? ?
Samples were cleared by ultracentrifugation with a TLA 100.3 rotor (Beckman Optima TL) at  ? ? ?
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4°C for 30 minutes and the supernatant taken for nuclear extract. Protein concentration was  ? ? ?
quantified using a modified Bradford assay (Bio-Rad). 1mg of nuclear extract was adjusted to  ? ? ?
300µl total volume with NE buffer to perform IP in duplicate. Protein G Dynabeads or  ? ? ?
Streptavidin M-280 Dynabeads (Life Technologies) were washed three times in PBS with 0.1%  ? ? ?
Tween-20 and 0.1% BSA. Nuclear extracts were cleared for 30 minutes at 4°C with 25µl Protein  ? ? ?
G Dynabeads. For streptavidin pulldown, 50µl of Streptavidin M-280 Dynabeads were added to  ? ? ?
the nuclear extract and incubated at 4°C for two hours with rotation. To test if the Tavi tag was  ? ? ?
required for streptavidin pulldown, nuclear extracts were split and incubated with or without  ? ? ?
200U TEV protease (Invitrogen) in the absence of a reducing agent and without agitation at 4°C  ? ? ?
for  4 hours prior to IP. For antibody immunoprecipitations, 5µg of antibody was added to the  ? ? ?
nuclear extract and incubated overnight at 4°C with rotation. Protein G beads were blocked in  ? ? ?
wash buffer overnight at 4°C with rotation. Blocked beads were then incubated with antibody- ? ? ?
bound nuclear extract for two hours at 4°C with rotation. Beads were washed four times in PBS  ? ? ?
with 0.1% Tween-20 and split into two equal volumes. Each sample was resuspended in 25µl  ? ? ?
loading buffer with 50mM DTT and boiled for 10 minutes at 95°C prior to loading on a 4-12%  ? ? ?
Bis-Tris NuPage gel (Life Technologies).  ? ? ?
  ? ? ?
Chromatin immunoprecipitation Forebrain tissues from male mice at 20 weeks of age were  ? ? ?
homogenized in cross-linking buffer (1% formaldehyde (wt/vol), 10mM HEPES (pH 7.5),  ? ? ?
100mM NaCl, 1mM EDTA, 1mM EGTA) and cross-linked for 5 minutes at RT. After quenching  ? ? ?
with 125mM glycine, cross-linked tissue was washed with ice-cold PBS and dounced with 16  ? ? ?
strokes in lysis buffer (50mM HEPES (pH 7.5), 140mM NaCl, 1mM EDTA, 1mM EGTA, 10%  ? ? ?
glycerol (vol/vol), 0.5% NP-40 (vol/vol), and 0.25% Triton X-100 (vol/vol) with protease  ? ? ?
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inhibitors). Nuclei were pelleted, washed and resuspended in chromatin buffer (10mM Tris-HCl  ? ? ?
(pH 8.0), 1mM EDTA, and 0.5mM EGTA with protease inhibitors). Chromatin was sonicated  ? ? ?
using a Diagenode Bioruptor, and salt and detergent were added to adjust the chromatin buffer to  ? ? ?
0.5% Triton X-100, 150mM NaCl, 10mM EDTA, and 0.1% sodium deoxycholate (DOC,  ? ? ?
vol/vol), and precleared at 4°C with Protein A Dynabeads (Invitrogen). For  ? ? ?
immunoprecipitation, 3µg of purified rabbit anti-MeCP2 IgG (in house) or non-specific rabbit  ? ? ?
IgG control (Millipore NI01) was incubated with 45µg of chromatin for 4 hours, followed by an  ? ? ?
overnight incubation with pre-blocked Protein A Dynabeads, at 4°C with rotation. Bead-bound  ? ? ?
chromatin was washed with low salt buffer (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA,  ? ? ?
1% Triton X-100, 0.1% DOC), high salt buffer (50mM HEPES pH 7.5, 500mM NaCl, 1mM  ? ? ?
EDTA, 1% Triton X-100, 0.1% DOC), LiCl buffer (50mM Tris-HCl pH 8.0, 150mM NaCl,  ? ? ?
1mM EDTA, 0.5% NP-40, 0.5% DOC) and TE buffer (10mM Tris-HCl pH 8.0, 1mM EDTA).  ? ? ?
Chromatin was eluted with elution buffer (50mM Tris-HCl pH 8.0, 10mM EDTA, and 1% SDS  ? ? ?
(wt/vol)), digested with proteinase K (0.5mg ml
-1
), and reversed crosslinked at 65°C overnight.  ? ? ?
After RNase A treatment, DNA fragments were extracted with phenol/chloroform and ethanol- ? ? ?
precipitated.  ? ? ?
 Quantitative real-time PCR (qPCR) analysis was carried out using SYBR green detection  ? ? ?
(Life Technologies) on an ABI Prism 7900HT Real-Time PCR System (Applied Biosystems).  ? ? ?
The percent input for each amplicon was determined by comparing the average threshold cycle  ? ? ?
of the immunoprecipitated DNA to a standard curve generated using serial dilutions of the input  ? ? ?
DNA and interpolating the fraction of input value for this sample.  ? ? ?
  ? ? ?
 45
Sub-nuclear Fractionation To prepare nucleoplasm-enriched proteins, cortices were dounce  ? ? ?
homogenized in 5 ml NE10 buffer (20 mM HEPES, pH 7.5, 10 mM KCl, 1 mM MgCl2, 0.1%  ? ? ?
Triton X-100, and 15 mM ȕ-mercaptoethanol) 30 times using a loose pestle. The resulting nuclei  ? ? ?
were washed with NE10 buffer and rotated in NE300 buffer (20 mM HEPES, pH 7.5, 300 mM  ? ? ?
NaCl, 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100, and 15 mM ȕ-mercaptoethanol) for 1 hour  ? ? ?
at 4°C. Samples were centrifuged at 500 g for 5 minutes, and the supernatant, which represents  ? ? ?
the nucleosolic fraction, was collected and saved. The insoluble pellet, consisting of the  ? ? ?
chromatin-bound fraction, was washed in NE150 buffer and incubated with 500 units of  ? ? ?
benzonase (Sigma-Aldrich) for 5 minutes at room temperature. The pellet was then resuspended  ? ? ?
in 50 ȝl NE150 buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM KCl, 1 mM MgCl2, 0.1%  ? ? ?
Triton X-100, and 15 mM ȕ-mercaptoethanol) and rotated for 1 hour at 4°C. Samples were  ? ? ?
centrifuged at 16,000 g, and the supernatant was collected as the chromatin-bound fraction.  ? ? ?
  ? ? ?
FACS Isolation of Neuronal Nuclei for RT-PCR and RNA-seq Nuclei were isolated from  ? ? ?
fresh cortical tissue for FACS under ice-cold and nuclease-free conditions. Mouse cortices were  ? ? ?
rapidly resected on ice and subjected to dounce homogenization in homogenization buffer  ? ? ?
(0.32M sucrose, 5mM CaCl2, 3mM MgAc2, 10mM Tris-HCl pH 8.0, 0.1% Triton, 0.1mM  ? ? ?
EDTA, Roche Complete Protease Inhibitor without EDTA). Homogenates were layered onto a  ? ? ?
sucrose cushion (1.8M sucrose, 10mM Tris-HCl pH 8.0, 3mM MgAc2 Roche Complete Protease  ? ? ?
Inhibitor without EDTA) and centrifuged in a Beckman Coulter L7 Ultracentrifuge at 25,000  ? ? ?
rpm at 4°C for 2.5 hours using a Beckman Coulter SW28 swinging bucket rotor. Nuclei were  ? ? ?
resuspended & washed once in blocking buffer (1x PBS, 0.5% BSA (Sigma A4503), RNasin  ? ? ?
Plus RNase Inhibitor (Promega)) and pelleted using a tabletop centrifuge at 5000 RCF at 4°C for  ? ? ?
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10 minutes. Nuclei were resuspended in blocking buffer to a concentration of ~6x10
6
 nuclei/ml,  ? ? ?
blocked for 20 minutes at 4°C with rotation, then incubated with Streptavidin Dylight 650  ? ? ?
(1:1000, Fisher 84547) and Alexa 488-conjugated anti-NeuN antibody (1:1000, Millipore  ? ? ?
MAB377X) for 30 minutes at 4°C with rotation. After a 5-minute incubation with 1:1000 DAPI  ? ? ?
to enable singlet detection during FACS, labeled nuclei were washed for an additional 30  ? ? ?
minutes at 4°C with blocking buffer, pelleted and resuspended in blocking buffer with 1% BSA.  ? ? ?
A BD Biosciences Influx cell sorter at the University of Pennsylvania Flow Cytometry and Cell  ? ? ?
Sorting Facility was used to identify cell type-specific populations of nuclei, and 1.2  2.5 x10
5
  ? ? ?
singlet nuclei from specified populations were directly sorted into Qiagen Buffer RLT Plus for  ? ? ?
immediate lysis and stabilization of RNA transcripts. Total nuclear RNA was processed using  ? ? ?
the Qiagen AllPrep DNA/RNA mini kit according to manufacturer instructions, with exception  ? ? ?
to the on-column DNaseI treatment. RNA was eluted from RNeasy mini spin columns and  ? ? ?
treated with DNaseI (Qiagen 79254) for 25 minutes at room temperature, then precipitated with  ? ? ?
glycogen/NaOAc and stored in ethanol at -80°C. Ethanol precipitation of nuclear RNA was  ? ? ?
carried out to completion prior to initiating RT-PCR or RNA-seq library construction.  ? ? ?
For RNA-seq, total RNA was prepared from FACS-isolated cortical nuclei of male mice  ? ? ?
at 6 weeks (TAVI, T158M, R106W, 2-3 mice pooled per biological replicate, 4 independently- ? ? ?
sorted biological replicates total) and female mice at 18 weeks (TAVI, T158M, R106W, 1 single  ? ? ?
mouse per biological replicate, 2 independently-sorted biological replicates total). No method of  ? ? ?
randomization was used to determine how animals were allocated to experimental groups, which  ? ? ?
was determined by genotype with matching age and sex. The numbers of biological replicates  ? ? ?
used for differential gene expression analysis are in compliance with ENCODE consortium long  ? ? ?
RNA-seq recommendations (2 replicates). Furthermore, the total amount of RNA isolated from  ? ? ?
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120,000-250,000 sorted nuclei was used as input for library construction; hence differential gene  ? ? ?
expression comparisons between FACS-isolated Mecp2 control and mutant neurons are  ? ? ?
performed using RNA from equivalent numbers of neuronal nuclei. Total RNA was depleted of  ? ? ?
ribosomal RNAs, subjected to 5 minutes of heat fragmentation, and converted to strand-specific  ? ? ?
cDNA libraries using the TruSeq Total RNA library prep kit with RiboZero depletion (Illumina).  ? ? ?
Multiplexed libraries were submitted for 100 paired-end sequencing on the Illumina HiSeq  ? ? ?
2000/2500 platform at the University of Pennsylvania Next Generation Sequencing Core facility,  ? ? ?
yielding approximately 30-40M total reads per library. 90-95% of total reads were uniquely  ? ? ?
mapped to the mouse Ensembl GRCm38/mm10 mouse genomic assembly.  ? ? ?
  ? ? ?
Real-Time PCR (RT-PCR) For RT-PCR of FACS-isolated cortical nuclei, total RNA was  ? ? ?
prepared (as described in preceding section) from 120,000 sorted nuclei of TAVI or R106W  ? ? ?
male mice at 6 weeks of age (2-3 mice pooled per biological replicate, 3 independently-sorted  ? ? ?
biological replicates total). For remaining RT-PCR assays, total RNA was isolated from whole  ? ? ?
tissue or unsorted cortical nuclei of WT, TAVI, T158M, or R106W mice as specified in figure  ? ? ?
legends (1 mouse per biological replicate, 3 biological replicates total). Total RNA was  ? ? ?
converted to cDNA with random hexamers using the SuperScript III First-Strand Synthesis  ? ? ?
System (Invitrogen). RT-PCR was performed on a ABI Prism 7900HT Real-Time PCR System  ? ? ?
(Applied Biosystems). To validate cell type-specific cortical nuclei populations (Fig. 2d and  ? ? ?
Supplementary Fig. 3i-j), exon-spanning Taqman gene expression assays to detect mRNA  ? ? ?
transcripts for the following genes: CRE (Mr00635245_cn), Mecp2 (Mm01193537_g1), Rbfox3  ? ? ?
(Mm01248771_m1), Gfap (Mm01253033_m1), Aif1 (Mm00479862_g1), Mog  ? ? ?
(Mm00447824_m1), Slc17a7 (Mm00812886_m1), Tbr1 (Mm00493433_m1), Gad1  ? ? ?
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(Mm04207432_g1), Slc35a1 (Mm00494138_m1), Ht3ar (Mm00442874_m1), Pvalb  ? ? ?
(Mm00443100_m1), Sst (Mm00436671_m1), Pgk1 (Mm00435617_m1), Actb  ? ? ?
(Mm00607939_s1), ß2m (Mm00437762_m1). A geometric mean was calculated to normalize  ? ? ?
mRNA expression levels to multiple housekeeping genes (Actb, ß2m, and Pgk1), and cell type- ? ? ?
enrichment for each sorted population was determined relative to the total mixed population of  ? ? ?
DAPI+ nuclei. For RT-PCR validation of low expressing genes and subcellular gene expression  ? ? ?
changes (Fig. 4h and Supplementary Figure 8), primers against primary transcripts and mRNAs  ? ? ?
were used (listed in Supplementary Table 2), and geometric means were calculated to normalize  ? ? ?
mRNA expression levels to multiple housekeeping genes (Actb, ß2m, and Pgk1).  ? ? ?
   ? ? ?
GRO-seq Nuclei were isolated from fresh cortical tissue of TAVI or R106W male mice at 6  ? ? ?
weeks of age (2 mice pooled per biological replicate, 2 biological replicates total) under ice-cold  ? ? ?
and nuclease-free conditions as described in the preceding section. After ultracentrifugation,  ? ? ?
nuclei were resuspended & washed once in PBS (1x PBS, RNasin Plus RNase Inhibitor  ? ? ?
(Promega)) and pelleted using a tabletop centrifuge at 5000 RCF at 4°C for 10 minutes. Nuclei  ? ? ?
were resuspended in PBS, pipetted through a 0.22µm filter and counted using a hemocytometer.  ? ? ?
Nuclei were then pelleted, resuspended to a concentration of 5×10
6
 - 10×10
6
 nuclei/100µl in  ? ? ?
glycerol storage buffer (50mM Tris pH 8.3, 40% glycerol, 5mM MgCl2, 0.1 mM), and flash  ? ? ?
frozen in liquid N2 for storage until needed.  ? ? ?
For each nuclear run-on (NRO), 100µl of nuclei was mixed with 46.5µl NRO Reaction  ? ? ? ?
Buffer (10mM Tris pH 8.0, 5mM MgCl2, 1 mM DTT, 300mM KCl), 3.5µl Nucleoside Mix  ? ? ? ?
(50µM ATP, 50µM GTP, 2µM CTP, 50µM Br-UTP, 0.4U/µl RNasin), and 50µl 2% Sarkosyl   ? ? ? ?
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Nuclear Run On Stop Solution (20mM Tris pH 7.4, 10mM EDTA, 2% SDS). The NRO reaction  ? ? ? ?
was performed at 30°C for 5 minutes, then terminated by a 20 minute incubation with DNAse I  ? ? ? ?
at 37°C, followed by a hour-long incubation with 225µl NRO Stop Buffer (20mM Tris, pH 7.4,  ? ? ? ?
10mM EDTA, 2% SDS) and Proteinase K at 55°C. Phenol-extracted RNA was fragmented with  ? ? ? ?
0.2N NaOH, and BrdU-RNA was isolated three consecutive times with BrdU-antibody beads,  ? ? ? ?
treated with enzymatic tobacco acid pyrophosphatase (TAP) and T4 polynucleotide kinase  ? ? ? ?
(PNK) to remove the cap and 3-phosphate and to add a 5-phosphate, as well as Illumina  ? ? ? ?
TruSeq small RNA sample prep kit adapter ligations between BrU-RNA isolation steps as  ? ? ? ?
described
41,59
.  ? ? ? ?
  ? ? ? ?
RNA-seq Mapping, Read Counting, and Differential Expression Analysis The mouse mm10  ? ? ? ?
genomic sequence (Mus_musculus.GRCm38.75.dna.primary_assembly.fa.gz) and gene  ? ? ? ?
information (Mus_musculus.GRCm38.75.gtf.gz) were downloaded from Ensembl release 75.  ? ? ? ?
The genome files used for mapping were built by STAR (version 2.3.0)
60
 using the parameters  ? ? ? ?
STAR --runMode genomeGenerate --runThreadN 12   ? ? ? ?
--genomeDir ./ --genomeFastaFiles Mus_musculus.GRCm38.75.dna.primary_assembly.fa.gz -- ? ? ? ?
sjdbGTFfile Mus_musculus.GRCm38.75.gtf --sjdbOverhang 100. The FASTQ files were  ? ? ? ?
mapped to the mouse Ensembl GRCm38/mm10 genome assembly by STAR (version 2.3.0)  ? ? ? ?
using the parameters --genomeDir ENSEMBL_75_mm10 --runThreadN 10 -- ? ? ? ?
outFilterMultimapNmax 1 --outFilterMismatchNmax 3. Perl scripts generated in-house were  ? ? ? ?
used to count the number of read pairs that mapped to genic regions (exon + intron) for each  ? ? ? ?
gene. If one end of a read pair overlapped with the annotated genomic region of a given gene and  ? ? ? ?
the other did not, the read pair was included in the final count for that gene. The total number of  ? ? ? ?
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read pairs that overlapped within a given gene represented the final read count for that gene. All  ? ? ? ?
intron and exon-mapped reads were used for differentially expressed gene comparisons, which  ? ? ? ?
were performed by using the R packages edgeR (v3.10.0)
61
 and DEseq2 (v1.8.0)
62
. Genes  ? ? ? ?
exhibiting low expression due to a substantially low number of mapped reads and whose edgeR  ? ? ? ?
CPM values satisfied the condition rowSums(cpm(data_y)) < 2 were filtered out from  ? ? ? ?
differential gene expression analyses. Conversely, genes with rowSums(cpm(data_y))  2 were  ? ? ? ?
retained for differential gene expression analyses. A false discovery rate < 0.05 was set to  ? ? ? ?
identify differentially expressed genes, and no fold change cutoff was applied. For each  ? ? ? ?
comparison, the results of both edgeR and DESeq2 analyses were merged into a final non- ? ? ? ?
redundant and FDR-controlled list of genes to avoid method-specific biases. The mean fold  ? ? ? ?
change and the mean FDR generated from both methods were used for generating plots and  ? ? ? ?
heatmaps.  ? ? ? ?
  ? ? ? ?
RNA Binding Protein (RBP) Data Pre-processing and Analysis To determine the enrichment  ? ? ? ?
of neuronally expressed RNA-binding proteins on gene transcripts, raw HITS-CLIP reads  ? ? ? ?
derived from the mouse brain were obtained from publically available datasets in the GEO  ? ? ? ?
repository (listed below). The quality of raw reads were assessed with FastQC
63
 and  ? ? ? ?
contaminants were removed using Trimgalore
64
 with parameters -q 15 --length 20 --stringency  ? ? ? ?
5. Remaining reads were aligned to a mouse reference genome derived from the Ensembl v75  ? ? ? ?
archived assembly using STAR (version 2.5)
60
 with parameters --outFilterMultimapNmax 1 -- ? ? ? ?
outFilterScoreMinOverLread 0 --outFilterMatchNminOverLread 0.5 --alignEndsType Local.  ? ? ? ?
Replicates were merged and then subsampled to match the sample with the lowest library size.  ? ? ? ?
Genome annotation from Ensembl v75 and in-house developed scripts facilitated the calculation  ? ? ? ?
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of RNA binding protein coverage in gene models. Genes not included in Groups A-H (Figure 4f)  ? ? ? ?
were filtered out. For k-means clustering of RBPs, raw read counts were first normalized using  ? ? ? ?
the variance stabilizing transformation function in DESeq2
62
, and the R packages factoextra,  ? ? ? ?
cluster, and NbClust were used to perform a Silhouette coefficient analysis and cluster genes  ? ? ? ?
based on the optimal k number of clusters. The Kruskal-Wallis test, followed by a post-hoc  ? ? ? ?
Wilcoxon Rank Sum Test with Holms correction for multiple comparisons, was used to identify  ? ? ? ?
statistically significant differences in RNA-binding protein enrichment within each gene cluster.  ? ? ? ?
RBP gene clusters were then used to perform One-tailed Fishers Exact Test with genes from  ? ? ? ?
Groups A-H to identify RBP enrichments that significantly associate with genes displaying  ? ? ? ?
subcellular differences in gene expression changes in R106W mutant mice.  ? ? ? ?
HITS-CLIP datasets used for RBP Analysis 
AGO2 (Rep 1-6/9-12) GSE73058 PMID: 26602609
APC (Rep 1-4) SRP042131 PMID: 25036633 
MBNL1 (Rep 1-2) GSE39911 PMID: 22901804 
MBNL2 (Rep 1-3) GSE38497 PMID: 22884328 
ELAVL1 (Rep 1-2) GSE45148 PMID: 21784246 
FMR1 (Rep 1-2) GSE45148 PMID: 21784246 
FUS (Rep 1-3) GSE40651 PMID: 23023293 
TAF15 (Rep 1-2) GSE43294 PMID: 23416048 
TDP43 GSE40651 PMID: 23023293 
RBFOX1 SRP030031 PMID: 24213538 
RBFOX2 SRP030031 PMID: 24213538 
RBFOX3 (Rep 1-5) SRP039559 - 
  ? ? ? ?
  ? ? ? ?
Functional Enrichment of Differentially Expressed Genes For DAVID gene ontology, a list  ? ? ? ?
of differentially expressed protein-coding genes was compared to a background list of actively  ? ? ? ?
expressed protein-coding genes from their respective cell type. Statistically significant terms  ? ? ? ?
(Benjamini P < 0.01, FDR < 0.05) were plotted for Figures S3C-D. For Gene Set Enrichment  ? ? ? ?
Analysis (GSEA), we performed a seeded, pre-ranked GSEA from lists of differentially  ? ? ? ?
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expressed protein-coding genes (ranked by fold change) using the September 2015 Mouse GO  ? ? ? ?
Gene Set Release (http://download.baderlab.org/EM_Genesets/September_24_2015/Mouse/).  ? ? ? ?
GSEA network associations (P-value < 0.1, Q-value < 0.1) were visualized using the Enrichment  ? ? ? ?
Map application (v2.0.1) in Cytoscape (v3.2.1)
65,66
, and clustered using gene set overlap  ? ? ? ?
coefficients.  ? ? ? ?
  ? ? ? ?
Principal Components Analysis (PCA) PCA analyses were performed with the top 500 genes  ? ? ? ?
exhibiting the highest row variance using the plotPCA function in the R package DESeq2.  ? ? ? ?
Principal components were plotted using Graphpad Prism version 6.0 for Mac (GraphPad  ? ? ? ?
Software, La Jolla California USA, www.graphpad.com).  ? ? ? ?
  ? ? ? ?
Determination of Actively Expressed Genes Actively expressed genes for excitatory and  ? ? ? ?
inhibitory neurons were determined by calculating the normalized FPKM (zFPKM) and using  ? ? ? ?
ZFPKM  3 for the active gene cutoff as previously described67.   ? ? ? ?
  ? ? ? ?
Statistical Analyses Statistical analyses were performed using Graphpad Prism version 6.0 for  ? ? ? ?
Mac (GraphPad Software, La Jolla California USA, www.graphpad.com) and R
68
. No statistical  ? ? ? ?
method was used to estimate sample size, as pre-specified effect sizes were not assumed. No  ? ? ? ?
animals or samples were excluded from analyses. Individual statistical tests are fully stated in the  ? ? ? ?
main text or figure legends. Comparisons of normally distributed data consisting of two groups  ? ? ? ?
with equal variances (F-test equality of variance P > 0.05) were analyzed using Students T-test,  ? ? ? ?
and unequal variances (F-test equality of variance P < 0.05) using Students T-test with Welchs  ? ? ? ?
correction for unequal variance. Comparisons of normally distributed data consisting of three or  ? ? ? ?
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more groups were analyzed using One-way ANOVA with the appropriate post-hoc test.  ? ? ? ?
Comparison of two or more factors across multiple groups was analyzed using a Two-way  ? ? ? ?
ANOVA with Sidaks correction for multiple comparisons. Comparisons of non-normally  ? ? ? ?
distributed data were analyzed using the Mann-Whitney/Wilcoxon test (two groups) or the  ? ? ? ?
Kruskal-Wallis test (three or more groups) with the appropriate post-hoc test. For multiple  ? ? ? ?
comparisons, all p-values are adjusted using the Holm-Bonferroni correction unless otherwise  ? ? ? ?
indicated. Experimental design and analytical details are also listed in the Life Sciences  ? ? ? ?
Reporting Summary.  ? ? ? ?
  ? ? ? ?
Main Figure Statistical Analyses  ? ? ? ?
Figure 1 Utilization and characterization of Mecp2
Tavi
 mice and associated RTT variants  ? ? ? ?
(e) nreplicates = 3, One-way ANOVA [F = 25.55, P = 0.0012]; Tukeys multiple comparisons  ? ? ? ?
correction applied. (f) Left, nWT = 4, nTAVI = 5, nT158M = 4, nR106W = 4; One-way ANOVA [F =  ? ? ? ?
12.4, P = 0.0004]; Sidaks multiple comparisons correction applied. Right, nWT = 4, nTAVI = 5,  ? ? ? ?
nT158M = 4, nR106W = 4;One-way ANOVA [F = 0.2977, P = 0.8264]; Sidaks multiple  ? ? ? ?
comparisons correction applied. (g) nWT = 20, nTAVI = 11, nKO = 6, nT158M = 6, nR106W = 12; One- ? ? ? ?
way ANOVA [F = 20.05, P < 0.0001]; Tukeys multiple comparison correction applied. (j) nWT  ? ? ? ?
= 31, nTAVI = 23, nKO = 17, nT158M = 39, nR106W = 26, Mantel-Cox [Ȥ2 = 109.3, df = 4, P <  ? ? ? ?
0.0001].  ? ? ? ?
  ? ? ? ?
Figure 2 Cell type-specific transcriptional profiling of neuronal nuclei   ? ? ? ?
(d) nreplicates = 3, Two-way ANOVA, Control [Cell Type-Gene Interaction, F = 42.68, P < 0.0001;  ? ? ? ?
Cell Type, F = 222.0, P < 0.0001; Gene, F =80.03, P < 0.0001], Non-Neuronal [Cell Type-Gene  ? ? ? ?
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Interaction, F = 12.47, P < 0.0001; Cell Type, F = 109.8, P < 0.0001; Gene, F = 7.655, P =  ? ? ? ?
0.0027], EXC-specific [Cell Type-Gene Interaction, F = 4.376, P = 0.0198; Cell Type, F = 1227,  ? ? ? ?
P < 0.0001; Gene, F = 0.3267, P = 0.5756], INH-specific [Cell Type-Gene Interaction, F =  ? ? ? ?
3.047, P = 0.0040; Cell Type, F = 646.5, P < 0.001; Gene, F = 2.916, P = 0.033]; Dunnetts  ? ? ? ?
multiple comparisons correction applied.  ? ? ? ?
  ? ? ? ?
Figure 3 T158M and R106W differentially expressed genes at 6 weeks of age  ? ? ? ?
(c) One-tailed Wilcoxon Signed Rank, Excitatory PUpregulated = 4.357e-3, Excitatory PDownregulated  ? ? ? ?
= 7.345e-3, Inhibitory PUpregulated = 4.575e-09, Inhibitory PDownregulated = 1.684e-05. (e) Chi-square  ? ? ? ?
Goodness-of-Fit, Excitatory PT158M < 2.2e-16 [Ȥ2 = 182.2, df = 2], Excitatory PR106W < 2.2e-16  ? ? ? ?
[Ȥ2 = 401.11, df = 2], Inhibitory PT158M < 2.2e-16 [Ȥ2 = 119.94, df = 2], Inhibitory PR106W < 2.2e- ? ? ? ?
16 [Ȥ2 = 346.86, df = 2]. (f) Two-tailed Kruskal-Wallis Rank Sum, Excitatory P  < 2.2e-16 [Ȥ2 =  ? ? ? ?
418.2, df = 3], Inhibitory P  < 2.2e-16 [Ȥ2 = 1026.9, df = 3]; Pairwise Wilcoxon Rank Sum P  ? ? ? ?
displayed.  ? ? ? ?
  ? ? ? ?
Figure 4 Genome-wide length-dependent transcriptional changes in RTT mutant mice  ? ? ? ?
(e) Top, n = 10,390 genes, Kolmogorov-Smirnov P < 2.2e-16 for each nascent or nuclear RNA  ? ? ? ?
versus whole cell RNA comparison, no correction for multiple comparisons. (f) n = 10, 390  ? ? ? ?
genes, Kruskal-Wallis PGroup A < 2.2e-16 [Ȥ2 = 2664.8, df = 2], PGroup B < 2.2e-16 [Ȥ2 = 290.18, df  ? ? ? ?
= 2], PGroup C < 2.2e-16 [Ȥ2 = 2403.3, df = 2], PGroup D < 2.2e-16 [Ȥ2 = 319.36, df = 2], PGroup E <  ? ? ? ?
2.2e-16 [Ȥ2 = 1483.8, df = 2], PGroup F < 2.2e-16 [Ȥ2 = 1385.8, df = 2], PGroup G < 2.2e-16 [Ȥ2 =  ? ? ? ?
2522.9, df = 2], PGroup H < 2.2e-16 [Ȥ2 = 2442.7, df = 2]; Pairwise Wilcoxon Rank Sum P  ? ? ? ?
displayed. (h) Left, Primary Transcripts + mRNA RT-PCR (Group Trend), nGroup A/C = 7 genes,  ? ? ? ?
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nGroup B = 5 genes, nGroup D = 5 genes, Two-way ANOVA, [Subcellular Compartment-Gene Group  ? ? ? ?
Interaction, F = 5.699, P = 0.0084; Subcellular Compartment, F = 1.419, P = 0.2436; Gene  ? ? ? ?
Group, F = 16.14, P < 0.0001]; Sidaks multiple comparisons correction applied. Right, Primary  ? ? ? ?
Transcripts only RT-PCR (Group Trend), nGroup A/c = 7 genes, nGroup B = 5 genes, nGroup D = 5  ? ? ? ?
genes, Two-way ANOVA, [Subcellular Compartment-Gene Group Interaction, F = 0.182, P =  ? ? ? ?
0.8345; Subcellular Compartment, F = 0.1334, P = 0.7176; Gene Group, F = 15.12, P <0.0001];  ? ? ? ?
Sidaks multiple comparisons correction applied.  ? ? ? ?
  ? ? ? ?
Figure 5 T158M and R106W differentially expressed genes in mosaic female mice  ? ? ? ?
(a) Two-way ANOVA [Genotype-Time Interaction, F = 2.987, P = 0.0712; Genotype, F = 41.14,  ? ? ? ?
P < 0.0001; Time, F = 7.332, P = 0.0129; Subjects (matching), F = 1.873, P = 0.0744]. (b)  ? ? ? ?
FACS isolation of cortical mosaic excitatory neuronal nuclei from heterozygous TAVI, T158M,  ? ? ? ?
or R106W female mice. (c) nT158M = 4, nR106W = 9, Two-way ANOVA [Population-Genotype  ? ? ? ?
Interaction, F = 0.3320, P = 0.5703; Population, F = 111.1, P < 0.0001; Genotype, F = 0.332, P =  ? ? ? ?
0.5703]. (d) nTAVI = 12, nT158M = 4, nR106W = 9, One-way ANOVA [F = 0.9376, P = 0.4067]. (h)  ? ? ? ?
One-tailed Fishers Exact Test [Odds Ratio = 19.3, P = 2.43e-05]. (i) One-tailed Wilcoxon  ? ? ? ?
Signed Rank, PTotal Overlap = 0.0331, PCell. Auto. = 0.5778, PNon-Cell Auto. = 8.825e-06.  ? ? ? ?
  ? ? ? ?
  ? ? ? ?
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